

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 December 2002 (19.12.2002)

PCT

(10) International Publication Number
WO 02/100846 A1(51) International Patent Classification⁷: C07D 277/28,
C07C 233/87, C07D 307/81, 333/24, C07C 311/29,
311/19, C07D 233/54, 261/08, 263/56, 307/52, 407/04,
417/04, 333/20, 409/04, 231/20Memorial Drive, Cambridge, MA 02139 (US). WANG,
Wuyi [CA/CA]; 2297 Frenette, Ville St-Laurent, Québec
H4R 1M3 (CA).

(21) International Application Number: PCT/CA02/00877

(74) Agents: OGILVY RENAULT et al.; Suite 1600, 1981
McGill College Avenue, Montreal, Québec H3A 2Y3
(CA).

(22) International Filing Date: 11 June 2002 (11.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/296,732 11 June 2001 (11.06.2001) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.(71) Applicant (*for all designated States except US*): SHIRE
BIOCHEM INC. [CA/CA]; 275 Armand-Frappier Blvd.,
Laval, Québec H7V 4A7 (CA).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).(71) Applicant (*for US only*): NGUYEN BA, Nghe [CA/CA];
175 Leotable Dubuc, LaPrairie, Québec J5R 5M5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CHAN, Chun,
Kong, Laval [CA/CA]; 27 Levere Street, Kirkland,
Québec H9J 3X8 (CA). BÉDARD, Jean [CA/CA]; 437
Lansdowne, Rosemère, Québec J7A 3G6 (CA). DAS, San-
joy, Kumar [IN/CA]; 553, 2ième rue, Laval, Québec H7V
1H7 (CA). PEREIRA, Oswy, Z. [CA/CA]; 12 Daudelin,
Kirkland, Québec H2J 1L8 (CA). SHUTTLEWORTH,
Steve [CA/US]; 2 Corporate Drive, South San Francisco,
CA 94080 (US). SIDDIQUI, M., Arshad [CA/US]; 840


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/100846 A1

(54) Title: COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

(57) Abstract: the present invention provides novel compounds represented by formula I: or
pharmaceutically acceptable salts thereof useful for treating Flaviviridae viral infection.

COMPOUNDS AND METHODS FOR THE TREATMENT
OR PREVENTION OF FLAVIVIRUS INFECTIONS

5 FIELD OF THE INVENTION

The present invention relates to biaryl compounds and a method for the treatment or prevention of *Flavivirus* infections using biaryl compounds.

10

BACKGROUND OF THE INVENTION

Hepatitis is a disease occurring throughout the world. It is generally of viral nature, although there are other causes known.
15 Viral hepatitis is by far the most common form of hepatitis. Nearly 750,000 Americans are affected by hepatitis each year, and out of those, more than 150,000 are infected with the hepatitis C virus ("HCV").

20 HCV is a positive-stranded RNA virus belonging to the *Flaviviridae* family and has closest relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary negative-strand RNA template. Due to the lack of
25 efficient culture replication system for the virus, HCV particles were isolated from pooled human plasma and shown, by electron microscopy, to have a diameter of about 50-60 nm. The HCV genome is a single-stranded, positive-sense RNA of about 9,600 bp coding for a polyprotein of 3009-3030 amino-acids, which is cleaved co
30 and post-translationally by cellular and two viral proteinases into mature viral proteins (core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). It is believed that the structural proteins, E1 and E2, the major glycoproteins are embedded into a viral lipid envelope and form stable heterodimers. It is also believed that
35 the structural core protein interacts with the viral RNA genome to form the nucleocapsid. The nonstructural proteins designated NS2 to NS5 include proteins with enzymatic functions involved in virus replication and protein processing including a polymerase, protease and helicase.


The main source of contamination with HCV is blood. The magnitude of the HCV infection as a health problem is illustrated by the prevalence among high-risk groups. For example, 60% to 90% of hemophiliacs and more than 80% of intravenous drug abusers in western countries are chronically infected with HCV. For intravenous drug abusers, the prevalence varies from about 28% to 70% depending on the population studied. The proportion of new HCV infections associated with post-transfusion has been markedly reduced lately due to advances in diagnostic tools used to screen blood donors.

The only treatment currently available for HCV infection is interferon- α (IFN- α). However, according to different clinical studies, only 70% of treated patients normalize alanine aminotransferase (ALT) levels in the serum and after discontinuation of IFN, 35% to 45% of these responders relapse. In general, only 20% to 25% of patients have long-term responses to IFN. Clinical studies have shown that combination treatment with IFN and ribavirin (RIBA) results in a superior clinical response than IFN alone. Different genotypes of HCV respond differently to IFN therapy, genotype 1b is more resistant to IFN therapy than type 2 and 3.

There is therefore a great need for the development of anti-viral agents.

SUMMARY OF THE INVENTION


The present invention provides compound of formula I:



and pharmaceutically acceptable salts thereof,

wherein,

M is chosen from:



5

wherein each R_6 is independently chosen from H or C_{1-6} alkyl;

A^1 is chosen from a bond, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

10

A is chosen from $COOR_5$, $CO-COOR_5$, $PO_3R_5R_5$, SO_3R_5 , tetrazole, $CON(R_5)CH(R_5)-COOR_5$, $CONR_5R_5$, $CONR_5OH$, wherein each R_5 is independently chosen from H or C_{1-6} alkyl;


15

R_1 , R_2 are independently chosen from H, C_{1-6} alkyl, C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl;

R_3 is chosen from C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl;

20

Y is chosen from:



25

Z is chosen from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-14} aryl, C_{3-10} heterocycle;

R₄ is chosen from H, halogen, CN, NO₂, C₁₋₆ alkyl, C₆₋₁₂ aryl, C₃₋₁₀ heterocycle, C₆₋₁₂ aralkyl, C₃₋₁₀ heteroaralkyl, NR₅R₅, SO₂CH₃, O-C₁₋₆ alkyl, O-C₆₋₁₂ aryl, O-C₆₋₁₂ aralkyl, COR₇,

wherein each R₅ is independently chosen from H or C₁₋₆ alkyl,
5 and R₇ is chosen from C₆₋₁₂ aryl or C₃₋₁₀ heterocycle;

with the proviso that compound of formula (I) is other than 3-[3-(2,6-Dichloro-pyridin-4-yl)-1-(4-thiophen-2-yl-benzyl)-ureido]-3-thiophen-2-yl-propionic acid; compound #1 .

10

The compounds of the present invention are useful in therapy, particularly as antivirals.

In another aspect, there is provided a method of treating viral
15 infections in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or composition of the invention.

In still another aspect, there there is provided a method of
20 treating viral infections in a subject in need of such treatment comprising administering to the subject a combination comprising at least one compound of formula (I) and at least one further therapeutic agent.


25 In another aspect, there is provided a pharmaceutical formulation comprising the compound of the invention in combination with a pharmaceutically acceptable carrier or excipient.

30 In another aspect of the invention is the use of a compound according to formula (I), for the manufacture of a medicament for the treatment of viral infections.


DETAILED DESCRIPTION OF THE INVENTION

35 In one embodiment, compounds of the present invention comprise those wherein the following embodiments are present, either independently or in combination.


In a further embodiment, M is



In an alternative embodiment, M is



5 In a further embodiment, M is



In a further embodiment, M is



- 10 In a further embodiment, M is a bond.
 In a further embodiment, A is chosen from COOH or COOCH₂CH₃.
 In a further embodiment, A is COOH.
 In a further embodiment, A is COOCH₂CH₃.
- 15 In a further embodiment, A¹ is chosen from -CH₂, C=CH, CH-CH₂ or a bond.
 In a further embodiment, A¹ is a bond.
 In a further embodiment, A¹ is CH₂.
- 20 In a further embodiment, R₂ is H or methyl.
 In a further embodiment, R₂ is H.
 In a further embodiment, R₂ is methyl.

In one embodiment, R_1 is chosen from benzyl, thiophene, CH_2 -thiophene, methyl, CH_2 -imidazole, CH_2 -cyclohexyl which can be unsubstituted or substituted by at least one substituent chosen from halogen, OH or benzyl.

5

In one embodiment, R_1 is benzyl substituted with OH.

In one embodiment, R_1 is benzyl substituted with Br.

In one embodiment, R_1 is CH_2 -thiophene substituted with Br.


In one embodiment, R_1 is CH_2 -cyclohexyl substituted with benzyl.

10

In a further embodiment, R_2 is chosen from a C_{6-12} aryl or C_{3-10} heterocycle.

In a further embodiment, R_3 is chosen from:

15 wherein:



Rw is H or methyl;

Ry is H or methyl;

Rw is H;

5 Rw is methyl;

Ry is H;

Ry is methyl;

And wherein, Xa is S, N, O or C.

10

In a further embodiment, each of Ra, Rb, Rc, Rd, Re, and Rf are independently chosen from, H, Cl, Br, I, F, C₁₋₆ alkyl, C₂₋₆ alkenyl, OC₁₋₆ alkyl, CF₃, COOH, OH, COOC₁₋₆ alkyl, CN, NH₂, NO₂, NH(C₁₋₆ alkyl), N(C₁₋₆ alkyl)₂.

15

In a further embodiment, each of Ra, Rb, Rc, Rd, Re, and Rf are independently chosen from, H, Cl, Br, I, F, methyl, O-methyl, vinyl, CF₃, COOH, COOCH₃, OH, CN, NH₂, NO₂, NH(CH₃) or N(CH₃)₂.

20

In a further embodiment, each of Ra, Rb, Rc, Rd, Re, and Rf are independently chosen from, H, Cl, Br, I, F, methyl, O-methyl, CF₃, COOH, COOCH₃, OH, CN, NH₂, or NO₂.

25

In a further embodiment, each of Ra, Rb, Rc, Rd, Re, and Rf are independently chosen from, H, Cl, methyl, O-methyl, CF₃, COOH, COOCH₃, CN, NH₂, or NO₂.

30

In a further embodiment, each of Ra, Rb, Rc, Rd, Re, and Rf are independently chosen from, H, Cl, F, methyl, OH, CF₃ or O-methyl.

In one embodiment, Rf is H or methyl.

In another embodiment, Rf is H.

In another embodiment, Rf is methyl.

35

In a further embodiment, each of Ra, Rb, Rc, Rd and Re is independently chosen from, H or Cl.

In a further embodiment, each of Ra, Rb, Rc, Rd and Re is H.

In one embodiment:

Ra is chosen from Cl, F, methyl or O-methyl;

Rb is H;

Rc is chosen from Cl, F, methyl or O-methyl;

Rd is H;

Re is H.

5

In one embodiment:

Ra is Cl;

Rb is H;

Rc is Cl;

10

Rd is H;

Re is H.

In one embodiment:

Ra is methyl;

15

Rb is methyl;

Rc is O-methyl;

Rd is H;

Re is methyl.

20

In a further embodiment, each of Rs, Rt, Ru, are independently chosen from, H, Cl, Br, I, F, C₁₋₆ alkyl, OC₁₋₆ alkyl, CF₃, COOH, COOC₁₋₆ alkyl, CN, NH₂, NO₂, NH(C₁₋₆ alkyl), N(C₁₋₆ alkyl)₂.

25

In a further embodiment, each of Rs, Rt, Ru, are independently chosen from, H, Cl, Br, I, F, methyl, O-methyl, CF₃, COOH, COOCH₃, CN, NH₂, NO₂, NH(CH₃) or N(CH₃)₂.

30

In a further embodiment, each of Rs, Rt, Ru, are independently chosen from, H, Cl, Br, I, F, methyl, O-methyl, CF₃, COOH, COOCH₃, CN, NH₂, or NO₂.

35

In a further embodiment, each of Rs, Rt, Ru, are independently chosen from, H, Cl, methyl, O-methyl, CF₃, COOH, COOCH₃, CN, NH₂, or NO₂.

In a further embodiment, each of Rs, Rt, Ru, are independently chosen from, H, Cl, F, methyl, CF₃ or O-methyl.

In a further embodiment, each of Rs, Rt, Ru, are independently chosen from, H or Cl.

In a further embodiment, each of Rs, Rt, Ru, are H.

5

In one embodiment:

Rs and Ru are Cl and Rt is H.

Rs is Cl, Rt and Ru are H.

- 10 In a further embodiment, Y is chosen from a bond, $-\text{CH}_2-$, CO or $-\text{CH}_2\text{CH}_2\text{COO}-$.

In a further embodiment, Y is a bond.

In a further embodiment, Y is $-\text{CH}_2-$.

In a further embodiment, Y is $-\text{CH}_2\text{CH}_2\text{COO}-$.

- 15 In a further embodiment, Y is CO.

- In one embodiment, Z is phenyl unsubstituted or substituted by at least one substituent chosen from halogen, C_{3-10} heterocycle, C_{3-10} heterocycle- COOCH_3 , NO_2 , CN, $\text{CO}-\text{C}_{6-12}$ aralkyl, COOC_{1-6} alkyl, C_{1-6} alkyl, $\text{O}-\text{C}_{1-6}$ alkyl, C_{6-12} aryl, $\text{O}-\text{C}_{6-12}$ aryl, C_{6-12} aralkyl, $\text{O}-\text{C}_{6-12}$ aralkyl.
- 20

- In another embodiment, Z is phenyl unsubstituted or substituted by at least one substituent chosen from Br, I, F, Cl, thiophene, thiazole, benzofuran, benzooxazole, furan- COOCH_3 , thiophene- COOCH_3 , NO_2 , CN-phenyl, chloro-benzoyl, difluoro-benzoyl, CO-methyl-isoxazole substituted with chlorophenyl, dichloro-benzoyl, CH_3 , CF_3CH_2 , SO_2CH_3 , OCH_3 , OCH_2 -fluoro-phenyl, O-chloro-phenyl, OCH_2 -phenyl, benzyloxi.
- 25

30

In one embodiment, Z is furan unsubstituted or substituted by at least one substituent chosen from halogen, C_{6-12} aryl, C_{3-10} heterocycle.

- 35 In another embodiment, Z is furan unsubstituted or substituted by at least one substituent chosen from Br, Cl-phenyl, CF_3CH_2 -phenyl, Br-phenyl, Cl-phenyl- CH_2CF_3 , NO_2 -phenyl, Cl-phenyl-Cl, Cl-phenyl-F, ethyl benzoate, benzoic acid, F-phenyl-F, tolyl, F-

phenyl, benzofuran, thiazole, Cl-thiophene, methoxy-furan, pyridine.

5 In one embodiment, Z is thiophene unsubstituted or substituted by at least one substituent chosen from halogen, C₆₋₁₂ aryl, C₃₋₁₀ heterocycle, nitro.

10 In another embodiment, Z is thiophene unsubstituted or substituted by at least one substituent chosen from Br, benzoic acid, ethyl benzoate, methyl benzoate, Cl-phenyl-Cl, Cl-phenyl-F, F-phenyl-F, F-phenyl, methoxy phenyl, tolyl, CN-phenyl, methyloxi-phenyl, trifluoromethyloxi-phenyl, trifluoromethyl-phenyl, S-CH₃-phenyl, benzofuran, thiazole, thiophene, Cl-thiophene, pyridine, pyridinyl, NO₂.

15 In one embodiment, Z is thiazole unsubstituted or substituted by at least one substituent chosen from halogen, C₁₋₆ alkyl, NR₃R₃, C₃₋₁₀ heterocycle.

20 In another embodiment, Z is thiazole unsubstituted or substituted by at least one substituent chosen from Cl, CF₃CH₂, diethylamino, piperidine, piperazine-phenyl, piperazine-benzyl.

25 In another embodiment, Z is a C₆₋₁₂ aryl chosen from naphthalene, anthraquinonyl.

30 In another embodiment, Z is a C₃₋₁₀ heterocycle chosen from benzofuran, pyrazole, methyl oxazole, pyrrolidine, piperidine, pyridine, pyrrole, quinolinyl unsubstituted or substituted by at least one substituent chosen from chlorophenyl-ketone, dichlorophenoxy, chlorophenoxy, dichlorophenyl, COO-t-butyl, tolyl-sulfonyl, COO-benzyl, CF₃.

35 In another embodiment, Z is chosen from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl chosen from vinyl, allyl, methyl, propyl, propynyl, thiazole unsubstituted or substituted by at least one substituent chosen from benzofuran.

In one embodiment, the viral infection is chosen from *Flavivirus* infections.


In one embodiment, the *Flavivirus* infection is chosen from Hepatitis C virus (HCV), bovine viral diarrhea virus (BVDV), hog
5 cholera virus and yellow fever virus.

In one embodiment, the *Flavivirus* infection is Hepatitis C virus (HCV).

In further embodiments, the present invention provides;

10 A method for treating or preventing a *Flaviridae* viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (I).

A method for treating or preventing a *Flaviridae* viral infection
15 in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (XV):



20

A method for treating or preventing *Flaviridae* infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (I) and at least one further antiviral agent.

25

A method for treating or preventing *Flaviridae* infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (XV) and at least one further antiviral agent.

30

In one embodiment, the antiviral agent is chosen from a viral serine protease inhibitor, viral polymerase inhibitor and viral helicase inhibitor.

In one embodiment, the antiviral agent is chosen from interferon α and ribavirin.

5 In one embodiment, said compound of formulae (I) or (XV) and said antiviral agent are administered sequentially.

In a further embodiment, said compound of formulae (I) or (XV) and said antiviral agent are administered simultaneously.

10 In further embodiments, the present invention provides a method for treating or preventing a *Flaviridae* viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (I). further comprising at least one additional agent chosen from immunomodulating agent, antioxidant agent, antibacterial agent
15 or antisense agent.

In one embodiment, the additional agent is chosen from silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
20

In a further embodiment, the additional agent are administered sequentially.

25 In still a further embodiment, said compound and said additional agent are administered simultaneously.

In a further embodiment, the *Flaviviridae* infection is hepatitis C (HCV).

30 In further embodiments, the present invention provides; A pharmaceutical composition for treating or preventing a *Flaviviridae* viral infection comprising administering at least one compound according to formula (I), together with at least one pharmaceutically acceptable carrier or excipient.

35 A pharmaceutical composition, further comprising one or more additional agent chosen from antiviral agent, immunomodulating agent, antioxidant agent, antibacterial agent or antisense agent.

In one embodiment, the antiviral agent is chosen from a viral serine protease inhibitor, viral polymerase inhibitor and viral helicase inhibitor.

5

In one embodiment, the antiviral agent is chosen from interferon α and ribavirin.

10

In one embodiment, the additional agent is chosen from silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.

In one embodiment, the *Flaviviridae* viral infection is hepatitis C viral infection (HCV).

15

In one embodiment, the present invention provides the use of a compound according to formula (I) for the manufacture of a medicament for treating or preventing a viral *Flaviviridae* infection in a host.

20

In one embodiment, the *Flaviviridae* infection is hepatitis C viral infection (HCV).

In one embodiment, the invention provides the use of a compound according to formula (I) for use in therapy.

25

In one embodiment, the present invention provides the use of a compound according to formula (I) for treating or preventing *Flaviviridae* viral infection in a host.

30

In one embodiment, the invention provides the use of a compound according to formula (I) for treating or preventing *Flaviviridae* viral infection in a host, further comprising one or more additional agent chosen from antiviral agent, immunomodulating agent, antioxidant agent, antibacterial agent or antisense

35

agent.

In one embodiment the antiviral agent is chosen from a viral serine protease inhibitor, viral polymerase inhibitor and viral helicase inhibitor.

In a further embodiment, the antiviral agent is chosen from interferon α and ribavirin.


- 5 In a further embodiment, the additional agent is chosen from silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
In still a further embodiment, the compound of formula (I) and said additionnal agent are administered sequentially.

10

In still a further embodiment, the compound of formula (I) and said additionnal agent are administered simultaneously.


- In a further embodiment, the Flaviviridea viral infection is hepatitis C viral infection (HCV).
15

- In one embodiment, there is provided a method for inhibiting or reducing the activity of viral polymerase in a host comprising administering a therapeutically effective amount of a compound
20 having the formula (I):



and pharmaceutically acceptable salts thereof,

- 25 wherein, M is chosen from:



wherein each R_6 is independently chosen from H or C_{1-6} alkyl;

5 A^1 is chosen from a bond, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;


A is chosen from $COOR_5$, $CO-COOR_5$, $PO_3R_5R_5$, SO_3R_5 , tetrazole, $CON(R_5)CH(R_5)-COOR_5$, $CONR_5R_5$, $CONR_5OH$, wherein each R_5 is independently chosen from H or C_{1-6} alkyl;

10

R_1 , R_2 are independently chosen from H, C_{1-6} alkyl, C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl;

15 R_3 is chosen from C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl;


Y is selected from the group consisting of:



20 Z is chosen from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-14} aryl, C_{3-10} heterocycle;

R_4 is chosen from H, halogen, CN, NO_2 , C_{1-6} alkyl, C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl, C_{3-10} heteroaralkyl, NR_5R_5 , SO_2CH_3 , $O-C_{1-6}$ alkyl, $O-C_{6-12}$ aryl, $O-C_{6-12}$ aralkyl, COR_7 ,
 25 wherein each R_5 is independently chosen from H or C_{1-6} alkyl, and R_7 is chosen from C_{6-12} aryl or C_{3-10} heterocycle.

30 In one embodiment, there is provided a method for inhibiting or reducing the activity of viral polymerase in a host comprising administering a therapeutically effective amount of a compound having the formula (XV):




In one embodiment, there is provided a method for inhibiting or reducing the activity of viral polymerase in a host comprising
 5 administering a therapeutically effective amount of a compound having the formulae (I) or (XV), further comprising one or more viral polymerase inhibitor.

In one embodiment, the viral polymerase is a *Flaviviridae* viral
 10 polymerase.

In one embodiment, the viral polymerase is a RNA-dependant RNA-polymerase.

15 In one embodiment, the viral polymerase is HCV polymerase.


In one embodiment, the invention provides a method for inhibiting or reducing the activity of viral helicase in a host comprising administering a therapeutically effective amount of a
 20 compound having the formula (I):



and pharmaceutically acceptable salts thereof,

25 wherein,

M is chosen from:



wherein each R_6 is independently chosen from H or C_{1-6} alkyl;

5 A^1 is chosen from a bond, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;


A is chosen from COOR_5 , CO—COOR_5 , $\text{PO}_3\text{R}_5\text{R}_5$, SO_3R_5 , tetrazole, $\text{CON(R}_5\text{)CH(R}_5\text{)—COOR}_5$, CONR_5R_5 , CONR_5OH , wherein each R_5 is independently chosen from H or C_{1-6} alkyl;

10

R_1 , R_2 are independently chosen from H, C_{1-6} alkyl, C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl;

15 R_3 is chosen from C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl;

Y is selected from the group consisting of:




20 Z is chosen from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-14} aryl, C_{3-10} heterocycle;

R_4 is chosen from H, halogen, CN, NO_2 , C_{1-6} alkyl, C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl, C_{3-10} heteroaralkyl, NR_5R_5 , SO_2CH_3 , O—C_{1-6} alkyl, O—C_{6-12} aryl, O—C_{6-12} aralkyl, COR_7 ,

25

wherein each R_3 is independently chosen from H or C_{1-6} alkyl, and R_7 is chosen from C_{6-12} aryl or C_{3-10} heterocycle.

In one embodiment, the invention provides a method for
5 inhibiting or reducing the activity of viral helicase in a host comprising administering a therapeutically effective amount of a compound having the formula (XV):



10

In further embodiments;

The viral helicase is a flaviviridea helicase.

The viral helicase is a HCV helicase.

15 In one embodiment, the invention provides the use of a compound according to formula (I) for inhibiting or reducing the activity of viral polymerase in a host.

In a further embodiment, the invention provides the use of a
20 compound according to formula (I) for inhibiting or reducing the activity of viral polymerase in a host, further comprising one or more viral polymerase inhibitor.

In one embodiment, the viral polymerase is *Flaviviridae* viral
25 polymerase.

In one embodiment, the viral polymerase is RNA-dependant RNA-polymerase.

30 In one embodiment, the viral polymerase is HCV polymerase.

In one embodiment, the invention provides the use of a compound according to formula (I) for inhibiting or reducing the activity of viral helicase in a host.

35

In one embodiment, the invention provides the use of a compound according to formula (I) for inhibiting or reducing the activity of viral helicase in a host, further comprising one or more viral helicase inhibitor.

5

In one embodiment, the viral helicase is *Flaviviridae* viral helicase.

In one embodiment, the viral helicase is HCV helicase.

10

In one embodiment, the invention provides a combination comprising a compound according to formula (I) and one or more additional agent chosen from viral serine protease inhibitor, viral polymerase inhibitor and viral helicase inhibitor, immunomodulating agent, antioxidant agent, antibacterial agent or antisense agent.

15

In further embodiments;

The additional agent is chosen from silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine, cyclosporin, interferon α and ribavirin.

20

The combination of said compound and said additional agent is administered sequentially.

25

The combination of said compound and said additional agent is administered simultaneously.

In another embodiment, the *Flavivirus* infection is Hepatitis C virus.

30

It will be appreciated by those skilled in the art that the compounds of formula (I) can contain a chiral centre on the general formula (I). The compounds of formula (I) thus exist in the form of two different optical isomers (i.e. (+) or (-) enantiomers). All such enantiomers and mixtures thereof including racemic mixtures are included within the scope of the invention. The single optical isomer or enantiomer can be

35

obtained by method well known in the art, such as chiral HPLC, enzymatic resolution and chiral auxiliary.

In accordance with the present invention, the compounds of
5 formula (I) include:

- (2s)-2-[(2,4-Dichloro-benzoyl)-(4-thiazol-2-yl-benzyl)-amino]-3-phenyl-propionic acid, compound #2
- (2s)-2-[(4-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-
10 propionic acid, compound #3
- (2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #4
- (2s)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #5
- 15 (2s)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #6
- (2s)-2-[(3-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #7
- 20 3-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-thiophen-2-yl-propionic acid ethyl ester, compound #8
- (2s)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #9
- (2s)-2-[(3-Bromo-benzyl)-(2-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #10
- 25 (2s)-2-[(3-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #11
- (2s)-2-[(2,4-Dichloro-benzoyl)-(4-iodo-benzyl)-amino]-3-phenyl-propionic acid, compound #12
- (2s)-2-[(3-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #13
- 30 (2s)-2-[(4-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #14
- (2s)-2-[(3-Bromo-benzyl)-(4-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #15
- 35 (2s)-2-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #16
- (2s)-2-[(3-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #17

(2s)-5-(4-[(1s-1-Carboxy-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl)-phenyl)-furan-2-carboxylic acid methyl ester, compound #18

5 (2s)-2-[(3-Bromo-benzyl)-(3,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #19

(2s)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #20

(2s)-3-(1-Benzyl-1*h*-imidazol-4-yl)-2-[(3-bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-propionic acid, compound # 21

10 (2s)-2-[(3-Bromo-benzyl)-[(2,4-dichloro-phenyl)-acetyl]-amino]-3-phenyl-propionic acid, compound #22

(2s)-5-(4-[(1s-1-Carboxy-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl)-phenyl)-thiophene-2-carboxylic acid methyl ester, compound #23

15 (2s)-2-[(2-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #24

(2s)-2-[(3-Bromo-benzyl)-(4-chloro-phenoxy-carbonyl)-amino]-3-phenyl-propionic acid, compound #25

20 (2s)-2-[(4-Benzoyl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid

(2s)-Triethyl-ammonium; 2-[(3-benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionate, compound #26

25 2-[Allyl-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid, compound #27

(2s)-2-[(3-Bromo-benzyl)-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #28

3-(4-Benzofuran-2-yl-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #29

30 (2s)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzyl)-amino]-3-phenyl-propionic acid, compound #30

(2s)-2-[(3-Benzofuran-2-yl-benzyl)-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #31

35 (2s)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid, compound #32

(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid, compound #33

- (2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-methyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #34
- (2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid, compound #35
- 5 (2s)-2-[(3-Bromo-benzyl)-(2-bromo-4-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #36
- (2s)-2-[(3-Benzofuran-2-yl-benzyl)-[(2,4-dichloro-phenyl)-acetyl]-amino]-3-phenyl-propionic acid, compound #37
- (2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-phenyl)-amino]-
- 10 3-phenyl-propionic acid, compound #38
- (2s)-2-[(2,4-Dichloro-benzoyl)-naphthalen-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #39
- (2s)-2-[(2,4-Dichloro-benzoyl)-(9,10-dioxo-9,10-dihydro-anthracen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound
- 15 #40
- (2s)-2-[[3-(3-Chloro-benzoyl)-benzyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #41
- (2s)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-difluoro-benzoyl)-benzyl]-amino]-3-phenyl-propionic acid, compound # 42
- 20 (2s)-2-[[3-[3-(2-Chloro-phenyl)-5-methyl-isoxazole-4-carbonyl]-benzyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound # 43
- (2s)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-dichloro-benzoyl)-benzyl]-amino]-3-phenyl-propionic acid, compound #44
- 25 (2s)-2-[(3-Benzooxazol-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #45
- (2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-ethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #46
- (2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-
- 30 amino]-3-cyclohexyl-propionic acid, compound #47
- (2s)-2-[(3-Benzofuran-2-yl-benzyl)-(4-chloro-2-methyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #48
- (2s)-2-[(3-Benzofuran-2-yl-benzyl)-(2-bromo-4-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #49
- 35 (2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-vinyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #50
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3-fluoro-benzyl)-amino]-3-phenyl-propionic acid, compound #51

(2s)-2-[(3-Chloro-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-

phenyl-propionic acid, compound #52

(2S)-2-[(2,4-Dichloro-benzoyl)-(3-nitro-benzyl)-amino]-3-phenyl-propionic acid, Compound #53

5 (2S)-2-[(3-Cyano-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #54

(2s)-2-[(2-Chloro-benzoyl)-[5-(3-chloro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #55

10 (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #56

(2s)-2-[(5-Bromo-furan-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #57

(2s)-2-[(5-Benzofuran-2-yl-furan-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #58

15 (2s)-2-[[5-(4-Bromo-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #59

(2s)-2-[[5-(2-Chloro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #60

20 (2s)-2-[[5-(2-Chloro-5-trifluoromethyl-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #61

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(2-nitro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #62

25 (3s)-3-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-4-phenyl-butyric acid, compound #63

2-[(2,4-Dichloro-benzoyl)-[2-(3-nitro-phenyl)-thiazol-5-ylmethyl]-amino]-3-phenyl-propionic acid, compound #64

30 (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3,4-dichloro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #65

(2s)-2-[Benzofuran-2-ylmethyl-(2,4-dichloro-benzyl)-amino]-3-phenyl-propionic acid, compound #66

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(2,4-dichloro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #67

35 (2s)-2-[(2-Bromo-4-chloro-benzoyl)-(5-bromo-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #68

(2s)-2-[[5-(3-Chloro-4-fluoro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #69

- (2s)-2-[[5-(4-Chloro-3-fluoro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #70
- (2s)-2-[(5-Bromo-furan-2-ylmethyl)-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid, compound #71
- 5 (2s)-2-(5-[[[1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-furan-2-yl)-benzoic acid ethyl ester, compound #72
- (2s)-2-(5-[[[1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-furan-2-yl)-benzoic acid, compound #73
- 10 (2s)-2-[(2,4-Dichloro-benzoyl)-(5-thiazol-2-yl-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #74
- (2s)-2-[(2,4-Dichloro-benzoyl)-furan-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #75
- (2s)-3-(5-[[[1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-furan-2-yl)-benzoic acid, compound #76
- 15 (2s)-4-(5-[[[1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-furan-2-yl)-benzoic acid, compound #77
- (2s)-2-[(2-Bromo-4-chloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #78
- 20 (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3,5-difluoro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #79
- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-m-tolyl-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #80
- 25 (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-fluoro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #81
- (2s)-2-[(5-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #82
- (2s)-4-(5-[[[1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-thiophen-2-yl)-benzoic acid, compound #83
- 30 (2s)-4-(5-[[[1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-thiophen-2-yl)-benzoic acid methyl ester, compound #84
- 35 (2s)-2-[(5-Benzofuran-2-yl-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #85
- 2-[(2-Benzofuran-2-yl-thiazol-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #86

(2s)-2-((2,4-Dichloro-benzoyl)-[4-(3,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #87

(2s)-2-[[4-(4-Chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #88

(2s)-2-[[4-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #89

(2s)-2-((2,4-Dichloro-benzoyl)-[4-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #90

(2s)-2-[[5-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #91

(2s)-2-[[5-(4-chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #92

(2s)-2-((2,4-Dichloro-benzoyl)-[5-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #93

(2s)-2-((2,4-Dichloro-benzoyl)-(5-thiazol-2-yl-thiophen-2-ylmethyl)-amino)-3-phenyl-propionic acid, compound #94

(2s)-2-((2,4-Dichloro-benzoyl)-[5-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #95

(2s)-2-((2,4-Dichloro-benzoyl)-[5-(3-methoxy-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #96

(2s)-2-((2,4-Dichloro-benzoyl)-[5-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #97

(2s)-2-[(2,4-Dichloro-benzoyl)-thiophen-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #98

(2s)-2-[(4-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #99

(2s)-2-((2,4-Dichloro-benzoyl)-[2-(4-phenyl-piperazin-1-yl)-thiazol-5-ylmethyl]-amino)-3-phenyl-propionic acid, compound #100

(2s)-1-(5-[[1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiazol-2-yl)-piperidine-4-carboxylic acid, compound #101

(2s)-2-[[2-(4-Benzyl-piperazin-1-yl)-thiazol-5-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #102

- (2s)-2-[(2,4-Dichloro-benzoyl)-(2-piperidin-1-yl-thiazol-5-ylmethyl)-amino]-3-phenyl-propionic acid, compound #103
- (2s)-2-[(2,4-Dichloro-benzoyl)-(2-diethylamino-thiazol-5-ylmethyl)-amino]-3-phenyl-propionic acid, compound #104
- 5 (2s)-2-[[2-(4-Chloro-benzoyl)-benzofuran-3-ylmethyl]-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #105
- (2s)-2-[[5-(2,4-Dichloro-phenoxy)-1-methyl-3-trifluoromethyl-1h-pyrazol-4-ylmethyl]-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-
- 10 amino]-3-phenyl-propionic acid, compound #106
- (2s)-2-[(2,4-Dichloro-benzoyl)-(2-[5-(2,4-dichloro-phenyl)-furan-2-yl]-2-oxo-ethyl)-amino]-3-phenyl-propionic acid, compound #107
- (2s)-2-Benzyl-4-(2,4-dichloro-phenyl)-3-[3-(2,6-dichloro-
- 15 phenyl)-5-methyl-isoxazol-4-ylmethyl]-4-oxo-butyric acid, compound #108
- (2s)-2-[Allyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #109
- (2s)-2-[(2,4-Dichloro-benzoyl)-methyl-amino]-3-phenyl-propionic
- 20 acid, compound #110
- (2s)-2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid, compound #111
- (2s)-2-[(2,4-Dichloro-benzoyl)-propyl-amino]-3-phenyl-propionic acid, compound #112
- 25 (2s)-2-[(3-Benzofuran-2-yl-prop-2-ynyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #113
- (2s)-2-[(4-Benzofuran-2-yl-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #114
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3-methyl-but-2-enyl)-amino]-3-
- 30 phenyl-propionic acid, compound #115
- 2-[(2-Bromo-allyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #116
- 3-[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-benzoic acid methyl ester, compound #117
- 35 3-[[5-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-5-phenyl-thiophene-2-carboxylic acid, compound #118
- 2-[[5-(3-Cyano-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #119

- (2s)-2-((2,4-Dichloro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #120
- (2s)-2-(5-([(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-2-yl)-benzoic acid ethyl ester, compound #121
- 3-(5-([(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-2-yl)-benzoic acid ethyl ester, compound #122
- (2s)-2-[[5-(3-Chloro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #123
- (2s)-2-[(4-Chloro-2-iodo-benzoyl)-(3,5-dibromo-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #124
- (2s)-3-(5-([(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-2-yl)-benzoic acid, compound #125
- (2s)-2-[[5-(5-Chloro-thiophen-2-yl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #126
- (2s)-2-[[2,2']Bithiophenyl-5-ylmethyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #127
- (2s)-2-[(5'-Chloro-[2,2']bithiophenyl-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #128
- (2s)-2-((2,4-Dichloro-benzoyl)-[4-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #129
- (2s)-2-((2,4-Dichloro-benzoyl)-[4-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #130
- (2s)-2-((4-Chloro-2-iodo-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #131
- (2s)-2-((4-Chloro-2-methyl-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #132
- (2s)-2-[(5-Chloro-[2,3']bithiophenyl-5'-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #133
- (2s)-2-((2,4-Dichloro-benzoyl)-[5-(4-methoxy-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #134
- (2s)-2-((2,4-Dichloro-benzoyl)-[5-(4-methoxy-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #135
- (2s)-2-((2,4-Dichloro-benzoyl)-[4-(4-methoxy-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid, compound #136

- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-pyridin-4-yl-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #137
- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #138
- 5 (2s)-2-[(2,4-Dichloro-benzoyl)-(4-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #139
- (2s)-2-[(2-Chloro-thiazol-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #140
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #141
- 10 (2s)-2-[(2,4-Dichloro-benzoyl)-(3,5-dichloro-benzyl)-amino]-3-phenyl-propionic acid, compound #142
- (2s)-2-[(2,4-Dichloro-benzoyl)-thiophen-3-ylmethyl-amino]-3-phenyl-propionic acid, compound #143
- 15 (2s)-2-[(2,4-Dichloro-benzoyl)-(3-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid, compound #144
- (2s)-2-[[3-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #145
- (2s)-2-[(3-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #146
- 20 (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-2-methyl-propionic acid, compound #147
- (2s)-2-[(2,4-Dichloro-benzoyl)-[2-(3-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-amino]-3-phenyl-propionic acid, compound #148
- 25 (2s)-2-[(2,4-Dichloro-benzoyl)-(5-nitro-thiophen-3-ylmethyl)-amino]-3-phenyl-propionic acid, compound #149
- (2s)-2-[(2,4-Dichloro-benzoyl)-(4-methanesulfonyl-benzyl)-amino]-3-phenyl-propionic acid, compound #150
- 30 (2s)-2-[(2,4-Dichloro-benzoyl)-(3-methoxy-benzyl)-amino]-3-phenyl-propionic acid, compound #151
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3-methyl-benzyl)-amino]-3-phenyl-propionic acid, compound #152
- (2s)-2-[[5-(3-Chloro-phenoxy)-1-methyl-3-trifluoromethyl-1h-pyrazol-4-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #153
- 35 (2s)-2-[(2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #154

(2s)-2-[(2,4-Dichloro-benzoyl)-[3-(3,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #155

5 (2s)-2-[[3-(4-Chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #156

(2s)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #157

10 (2s)-2-[(2,4-Dichloro-benzoyl)-(3-*m*-tolyl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #158

(2s)-2-(2-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-thiophen-3-yl)-benzoic acid ethyl ester, compound #159

15 (2s)-4-(2-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-thiophen-3-yl)-benzoic acid ethyl ester, compound #160

(2s)-2-[(2,4-Dichloro-benzoyl)-[3-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #161

20 (2s)-2-[[3-(3-Cyano-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #162

[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-thiophen-2-yl-acetic acid, compound #163

25 L-2-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-pyrrolidine-1-carboxylic acid #tert-butyl ester, compound #164

d-2-[[1-(1-carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-pyrrolidine-1-carboxylic acid #tert-butyl ester, compound #165

30 4-[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-piperidine-1-carboxylic acid benzyl ester, compound #166

1-2-[(2,4-Dichloro-benzoyl)-pyrrolidin-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #167

d-2-[(2,4-Dichloro-benzoyl)-pyrrolidin-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #168

35 3-(5-Bromo-thiophen-2-yl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #169

2-[(2,4-Dichloro-benzoyl)-pyridin-3-ylmethyl-amino]-3-phenyl-propionic acid, compound #170

- 2-[(2,4-Dichloro-benzoyl)-(4-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid, compound #171
- 2-[(2,4-Dichloro-benzoyl)-[4-(4-fluoro-benzyloxy)-benzyl]-amino]-3-phenyl-propionic acid, compound #172
- 5 2-[(2,4-Dichloro-benzoyl)-(4-fluoro-3-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid, compound #173
- 2-[(1-Benzenesulfonyl-1h-pyrrol-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #174
- 2-[[3-(4-Chloro-phenoxy)-benzyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #175
- 10 2-[(5-Chloro-2-chloromethyl-hepta-2,4,6-trienoyl)-quinolin-3-ylmethyl-amino]-3-phenyl-propionic acid, compound #176
- 2-[(2-Benzyloxy-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #177
- 15 2-[(2,4-Dichloro-benzoyl)-[3-(5-isopropyl-2-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #178
- 2-[(2,4-Dichloro-benzoyl)-[3-(4-trifluoromethoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound
- 20 #179
- 2-[(2,4-Dichloro-benzoyl)-[3-(3-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #180
- 2-[[3-(3,5-Bis-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound
- 25 #181
- 2-[(2,4-Dichloro-benzoyl)-(3-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #182
- 2-[(2,4-Dichloro-benzoyl)-[3-(4-methylsulfanyl-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #183
- 30 2-[(2,4-Dichloro-benzoyl)-[3-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #184
- 2-[(2,4-Dichloro-benzoyl)-(3-pyridin-3-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #185
- 35 2-[(2,4-Dichloro-benzoyl)-[1-(toluene-2-sulfonyl)-pyrrolidin-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #186
- 2-[(2-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #187

- 3-(2-Bromo-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #188
- 3-(4-Bromo-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #189
- 5 2-[(3-Bromo-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #190
- 2-[(4-Bromo-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #191
- 2-[[4-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #192
- 10 3-[[{(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-benzoic acid, compound #193
- 2-[(3-Amino-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #194
- 15 3-Phenyl-2-[(2-trifluoromethyl-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-propionic acid, Compound #195
- 2-[(3-Cyano-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, Compound #196
- 2-[(4-Nitro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, Compound #197
- 20 2-[(2-Fluoro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, Compound #198
- 2-[Benzyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid
- 25 Compound #199
- 2-[(2,4-DICHLORO-BENZOYL)-[3-(2H-TETRAZOL-5-YL)-BENZYL]-AMINO]-3-PHENYL-PROPIONIC ACID Compound #200
- 30 2-[(2,4-DICHLORO-BENZOYL)-(2-NITRO-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #201
- 2-[(2,4-DICHLORO-BENZOYL)-(4-NITRO-BENZYL)-AMINO]-3-PHENYL-PROPIONIC Compound #202
- 35 2-[(2-CYANO-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #203
- 2-[(4-CYANO-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #204
- 40

2-[[1-(3-CYANO-PHENYL)-ETHYL]-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #205

5 3-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid methyl ester Compound #206

3-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid Compound #207

10

2-[(2,4-DICHLORO-BENZOYL)-(3-METHANESULFONYL-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #208

15

2-[(3-ACETYL-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #209

2-[(2,4-DICHLORO-BENZOYL)-(1-OXY-PYRIDIN-3-YLMETHYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #210

20

2-{(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-amino}-3-phenyl-propionic acid Compound #211.

25

Preferably, the compounds of the present invention are provided in the form of a single enantiomer at least 95%, more preferably at least 97% and most preferably at least 99% free of the corresponding enantiomer.

30

More preferably the compound of the present invention is in the form of the (+) enantiomer at least 95% free of the corresponding (-) enantiomer.

35

More preferably the compound of the present invention is in the form of the (+) enantiomer at least 97% free of the corresponding (-) enantiomer.

40

More preferably the compound of the present invention is in the form of the (+) enantiomer at least 99% free of the corresponding (-) enantiomer.

In a more preferred embodiment, the compound of the present invention is in the form of the (-) enantiomer at least 95% free of the corresponding (+) enantiomer.

- 5 Most preferably the compound of the present invention is in the form of the (-) enantiomer at least 97% free of the corresponding (+) enantiomer.

- 10 More preferably the compound of the present invention is in the form of the (-) enantiomer at least 99% free of the corresponding (+) enantiomer.

- There is also provided a pharmaceutically acceptable salts of the present invention. By the term pharmaceutically acceptable salts of compounds of general formula (I) are meant those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

- Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium), ammonium and NR_4^+ (where R is C_{1-4} alkyl) salts.

Reference hereinafter to a compound according to the invention includes compounds of the general formula (I) and their pharmaceutically acceptable salts.

- 35 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other

references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to
5 be limiting.

As used in this application, the term "alkyl" represents an unsubstituted or substituted (by a halogen, nitro, SO_3R_4 , $\text{PO}_3\text{R}_4\text{R}_4$, CONH_2 , COOH , SR_5 , O-C_{1-6} alkyl, O-C_{2-6} alkenyl, O-C_{2-6} alkynyl, C_{6-12}
10 aryl, C_{3-10} heterocycle, hydroxyl, amino, NR_4R_4 , or COOQ , wherein Q is C_{1-6} alkyl; C_{2-6} alkenyl; C_{2-6} alkynyl, C_{6-12} aryl and R_4 is H, C_{1-6} alkyl) straight chain, branched chain or cyclic hydrocarbon moiety (e.g. isopropyl, ethyl, fluorohexyl or cyclopropyl). The term alkyl is also meant to include alkyls in which one or more
15 hydrogen atoms is replaced by an halogen, more preferably, the halogen is fluoro (e.g. CF_3 - or CF_3CH_2 -).

The terms "alkenyl" and "alkynyl" represent an alkyl containing at least one unsaturated group (e.g. allyl, acetylene,
20 ethylene).

The term "aryl" represents a carbocyclic moiety which may be substituted (by H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} heterocycle, halogen, nitro, aminoamidino, amidino, guanido,
25 CONH_2 , COOH , O-C_{1-6} alkyl, O-C_{2-6} alkenyl, O-C_{2-6} alkynyl, SCH_3 , SO_2CH_3 , amino, NR_4R_4 , hydroxyl or COOQ , wherein Q is C_{1-6} alkyl, C_{2-6} alkenyl, a C_{2-6} alkynyl) and containing at least one benzenoid-type ring (e.g., phenyl, naphthyl and anthraquinonyl). The term "aralkyl" represents an aryl group attached to the
30 adjacent atom by a C_{1-6} alkyl, C_{1-6} alkenyl, or C_{1-6} alkynyl (e.g., benzyl).

The term "heterocycle" represents a mono or di-substituted (e.g. by a C_{1-6} alkyl, O-C_{1-6} alkyl, O-C_{6-12} aryl, C_{6-12} aryl, C_{6-12} aralkyl, C_{3-10} heterocycle, halogen, amino, COOH , COOR_5 or NO_2 ; wherein R_5 is a C_{1-6} alkyl), or unsubstituted, saturated or unsaturated, cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom, e.g. oxygen, sulfur or nitrogen. It is understood that the term heterocyclic ring represents a mono or polycyclic
40 (e.g., bicyclic) ring. Examples of heterocyclic rings include

but are not limited to epoxide; furan; benzofuran; isobenzofuran; oxathiolane; dithiolane; dioxolane; pyrrole; pyrrolidine; imidazole; pyridine; pyrimidine; indole; piperidine; morpholine; thiophene and thiomorpholine.

5

The term "heteroaralkyl" represents an heterocycle group attached to the adjacent atom by a C₁₋₆ alkyl, C₁₋₆ alkenyl, or C₁₋₆ alkynyl (e.g., thiophenyl).

- 10 When there is a sulfur atom present, the sulfur atom can be at different oxidation levels, ie. S, SO, or SO₂. All such oxidation levels are within the scope of the present invention.

- 15 The term "independently" means that a substituent can be the same or different definition for each item.

- It will be appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of
20 administration, the nature of the condition for which treatment is required and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general however a suitable dose will be in the range of from about 0.1 to about 750 mg/kg of body weight per
25 day, preferably in the range of 0.5 to 60 mg/kg/day, most preferably in the range of 1 to 20 mg/kg/day.

- The desired dose may conveniently be presented in a single dose or as divided dose administered at appropriate intervals, for
30 example as two, three, four or more doses per day.

- The compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit
35 dosage form.

Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 µM, preferably about 2 to 50 µM, most preferably

- about 3 to about 30 μ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 500 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.
- While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation. The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

- Pharmaceutical formulation suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion. The active ingredient may also be

presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

The compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

For topical administration to the epidermis, the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Such transdermal patches may contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier..

Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in moulds.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

For intra-nasal administration the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base also comprising one more dispersing agents, solubilising agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs.

For administration by inhalation the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a

dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs
5 from which the powder may be administered with the aid of an inhalator or insufflator.

When desired the above described formulations adapted to give sustained release of the active ingredient may be employed.

10

The compounds of the invention may also be used in combination with other antiviral agents.

In one aspect of the invention, the compounds of the invention
15 may be employed together with at least one other antiviral agent chosen from protease inhibitors, polymerase inhibitors, and helicase inhibitors.

In another aspect of the invention, the compounds of the
20 invention may be employed together with at least one other antiviral agent chosen from Interferon- α and Ribavirin.


The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus
25 pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention.

The individual components of such combinations may be
30 administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When the compound (I) or a pharmaceutically acceptable salts thereof is used in combination with a second therapeutic agent
35 active against the same virus the dose of each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

The following general schemes and examples are provided to illustrate various embodiments of the present invention and shall not be considered as limiting in scope.

5 General scheme 1 for the preparation of biaryl carboxamide analogs with a five membered ring



10 The following compounds were prepared in a similar manner as described in general scheme 1:

compound #38 compound #55 compound #56 Compound #57 Compound #58
 Compound #59 compound #60 compound #61 compound #62 compound #63
 15 compound #64 compound #65 compound #66 compound #67 compound #68
 Compound #69 Compound #70 Compound #71 compound #72 compound #73
 compound #74 Compound #75 Compound #76 compound #77 compound #78
 compound #79 compound #80 compound #81 compound #82 compound #83
 compound #84 compound #85 compound #87 compound #88 compound
 20 #compound #90 compound #91 compound #92 compound #93 compound
 #94 compound #95 compound #96 compound #compound #98 compound
 #99 compound #100 compound #101 compound #102 compound #103
 compound #104 compound #105 compound #106 compound #107 compound
 #113 compound #120 compound #121 compound #122 compound #123
 25 compound #124 compound #125 compound #126 compound #127 compound
 #128 compound #129 compound #130 compound #131 compound #132
 compound #133 compound #134 compound #135 compound #136 compound
 #137 compound #138 compound #139 compound #140 compound #141
 compound #142 Bcompound #143 compound #144 compound #145
 30 compound #146 compound #147 compound #148 compound #149 compound


#150 compound #151 compound #152 compound #153 compound #154
 compound #155 compound #156 compound #157 compound #158 compound
 #159 compound #160 compound #161 compound #162 compound #163
 compound #164
 5 compound #165 compound #166 compound #167 compound #168 compound
 #169 compound #170 compound #171 compound #172 compound #173
 compound #174 compound #175 compound #176 compound #177 compound
 #178 compound #179 compound #180 compound #181 compound #182
 compound #183 compound #184 compound #185 compound #186 compound
 10 #187 compound #188 compound #189 compound #190 compound #191

Example 1

2-[(2,4-Dichloro-benzoyl)-(3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid compound #154

15 STEP I

2-[(3-Bromo-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid *tert*-butyl ester




20 To a stirred solution of 2-Amino-3-phenyl-propionic acid *tert*-butyl ester (50.6mg, 0.229 mmol) in ethanol (1 mL), were added 3-Bromo-thiophene-2-carbaldehyde (50mg, 0.208mmol.) and acetic acid (21 μ L). The reaction mixture was stirred at room temperature under nitrogen for 2 hrs as the progress of imine
 25 formation was monitored by TLC. Then, sodium cyanoborohydride (20mg, 0.312 mmol) was added. The mixture was acidified with sodium bicarbonate and then extracted with dichloromethane. After removal of the solvent, the crude product was purified by silica plate (hexane/ethylacetate 90%:10%) to give 2-[(3-Bromo-
 30 thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid *tert*-butyl ester in 80% yield : ^1H NMR (Varian 400MHz, CDCl_3) δ 7.23 (m, 6H, ArH), 6.90 (d, 1H, $J=5.3\text{Hz}$, thiophenH), 4.00 (d, 1H, $J=14.6\text{Hz}$, NCH_2), 3.85 (d, 1H, $J=14.6\text{Hz}$, NCH_2), 3.48 (m, 1H, CHCH_2), 3.00 (m, 2H, CHCH_2), 1.37 (s, 9H, tBu).

35

STEP II


2-[(3-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid *tert*-butyl ester



To a stirred solution of 2-[(3-Bromo-thiophen-2-ylmethyl)-
 5 amino]-3-phenyl-propionic acid *tert*-butyl ester (91.6mg,
 0.231mmol) in dichloromethane (3.3ml) and N,N-
 diisopropylethylamine (44μl) was added a solution of 2,4-
 Dichloro-benzoyl chloride (34μl, 0.243 mmol) in dichloromethane
 (1.3ml). The reaction mixture was stirred at room temperature
 10 under nitrogen overnight. Then, the mixture was extracted with
 sodium bicarbonate/dichloromethane. The extract was dried
 (sodium sulfate) and evaporated under reduced pressure to yield
 2-[(3-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-
 3-phenyl-propionic acid *tert*-butyl ester with 92% yield. ¹H
 15 NMR(Varian 400MHz, CDCl₃) δ(ppm) presence of rotomers 8.08 (d,
 0.5H, J=8.7Hz, ArH), 7.56 (d, 0.5H, J=2.0Hz, ArH), 7.40 (m, 2H,
 ArH), 7.23 (m, 2.5H, ArH), 6.99 (d, 0.5H, J=5.4Hz, ArH), 6.92
 (m, 2H, ArH), 6.83 (d, 0.5H, J=5.0Hz, ArH), 6.54 (d, 1H,
 J=7.1Hz, ArH), 5.78 (d, 0.5H, J=8.0Hz, ArH), 5.20 (m, 1H, NCH₂),
 20 4.85 (m, 1H, NCH₂), 4.16 (m, 1H, CHCH₂), 3.10 (m, 2H, CHCH₂), 1.47
 (s, 9H, tBu).

STEP III


25 2-[(2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-
 ylmethyl]-amino]-3-phenyl-propionic acid *tert*-butyl ester



To 3 mL of THF solution of 2-[(3-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid *tert*-butyl ester (50 mg, 0.0879mmol) was sequentially added tetrakis (triphenylphosphine)palladium(0) (10mg, 0.00878 mmol). To the resulting brown solution was added a THF solution of 3, 5-difluorozinc bromide (0.5M, 1.06 mL). The reaction was stirred and heated to reflux overnight. TLC showed complete conversion of the starting material to a less polar product. A few drop of acetic acid was added before complete removal of the solvent using a rotavap. The crude product was chromatographed to give 2-[(2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid *tert*-butyl ester, 37 mg, in 72% yield. ¹H NMR(Varian 400 MHz, CDCl₃), δ(ppm), presence of rotomers, 7.45 (m, <1H), 7.36 (s, <1H), 7.20 (m, ~8H), 7.05 (m, <1H), 6.98 (m, 1H), 6.90 (m, 4H), 6.82 (m, <1H), 6.51 (m, <1H), 5.80 (m, <1H), 5.20 (m, <1H), 4.84 (m, <1H), 4.18 (m, 2H), 3.38 (m, 2H), 2.90 (m, 1H), 1.33, 1.42, 1.44 (s, 9H).

STEP IV

2-[(2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid




To a stirred solution of 2-[(2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic

acid *tert*-butyl ester (37.63 mg, 0.0625mmol.) in dichloromethane (1ml.), was added trifluoroacetic acid (1ml.). The reaction mixture was stirred at room temperature during 1 hr. TLC monitored the progress of the reaction. When the reaction was completed, the mixture was concentrated under reduced pressure on a rotary evaporator, followed by silica chromatography using 90% ethylacetate, 10% methanol and 1 drop of acetic acid, afforded 2-((2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid in 85% yield. ¹H NMR (Varian 400MHz, CDCl₃) δ(ppm), 7.22 (m, 8H, ArH), 7.00 (m, 2H, ArH), 6.82 (m, 2H, ArH), 6.50 (m, 1H, ArH), 4.95 (m, 0.5H, NCH₂), 4.65 (m, 0.5H, NCH₂), 4.10 (m, 1H, NCH₂), 3.60 (m, 1H, CHCH₂), 3.20 (m, 1H, CHCH₂), 3.05 (m, 1H, CHCH₂). MS, 546.00 found.

15

General scheme 2 for the preparation of biaryl carboxamide analogs with six membered aromatic ring



The following compounds were prepared in a similar manner as described in general scheme 2:

compound #2 , compound #, compound #4 , compound #9 , Compound #10 , Compound #11 , Compound #12 Compound#15, Compound #19 , compound # 21 , compound #22 , compound #25 , compound #28 , compound #31 , Compound #, Compound #34 , Compound #35 , compound #36 , compound #37 , compound #39 , compound #, compound #41 , compound # 42 , compound # 43 , compound #44 ,

5 General scheme 3 for the preparation of biaryl sulfonamide
analogs with six membered aromatic ring spacer


Example 2

2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-
benzenesulfonyl)-amino]-3-phenyl-propionic acid Compound #5

10

STEP I

2-(4-Methoxy-2,3,6-trimethyl-benzenesulfonylamino)-3-phenyl-
propionic acid methyl ester




15

A solution of L-phenylalanine methyl ester (300 mg, 1.68 mmol) in anhydrous CH_2Cl_2 (10 mL) was cooled to 0°C in an ice bath, then triethylamine (0.35 mL), 4-methoxy-2,3,6-trimethyl-
20 benzenesulfonyl chloride (438 mg, 1.76 mmol) and catalytic amount of DMAP (25 mg) were added under a N_2 atmosphere. The reaction mixture was stirred at room temperature for 12h. After that period of time, the mixture was partitioned between water and CH_2Cl_2 , the organic layer was separated, dried (Na_2SO_4) and
25 concentrated. The residue was purified by silica gel column chromatography using ethyl acetate and hexane (1:2) as eluent to obtain 2-(4-Methoxy-2,3,6-trimethyl-benzenesulfonylamino)-3-phenyl-propionic acid methyl ester as a white solid, 500 mg (77%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.26-7.18 (m, 3H), 7.02-6.99 (m,
30 2H), 6.53 (s, 1H), 5.12 (d, 1H), 4.09-4.04 (m, 1H), 3.84 (s, 3H), 3.55 (s, 3H), 3.05 (dd, 1H), 3.03 (dd, 1H), 2.64, 2.38, 2.08 (3s, 9H).

STEP II


2-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid methyl ester



To a solution of 2-(4-Methoxy-2,3,6-trimethyl-
 5 benzenesulfonylamino)-3-phenyl-propionic acid methyl ester (50 mg,
 0.129 mmol) in anhydrous DMF (1 mL), 4-iodobenzyl bromide (46 mg,
 0.154 mmol) and cesium carbonate (50 mg, 0.154 mmol) were added
 and the reaction mixture was stirred at room temperature under a
 N₂ atmosphere for 12 h. The reaction mixture was partitioned
 10 between water and ether. The ether layer was separated, dried
 (Na₂SO₄), concentrated. The residue was purified by silica gel
 column chromatography using ethyl acetate and hexane (1:3) as
 eluent to obtain 2-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-
 benzenesulfonyl)-amino]-3-phenyl-propionic acid methyl ester (68
 15 mg, 90%) as a foam. ¹H NMR (CDCl₃, 400 MHz): δ 7.48 (d, 2H), 7.21
 (m, 3H), 7.09 (d, 2H), 6.91 (d, 2H), 6.45 (s, 1H), 4.60 (m, 3H),
 3.81 (s, 3H), 3.38 (s, 3H), 3.17 (dd, 1H), 2.81 (dd, 1H), 2.63,
 2.44, 2.14 (3s, 9H).

STEP III


2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid methyl ester.



- 5 To a degassed solution of 2-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid methyl ester (40 mg, 0.068 mmol) and benzofuran-2-boronic acid (20 mg, 0.124 mmol) in a mixture of DME (3 mL) and 2M aqueous Na_2CO_3 (1.5 mL), $\text{Pd(PPh}_3)_4$ (4 mg) was added and the reaction mixture was
- 10 stirred at 65°C for 2h under a N_2 atmosphere. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated, dried (Na_2SO_4), concentrated. The residue was purified by column chromatography using ethyl acetate and hexane (1:9) to obtain 2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-
- 15 2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid methyl ester (39 mg, 100%) as a thick syrup. ^1H NMR (af-2783) (CDCl_3 , 400 MHz): δ 7.2 (d, 2H), 7.62 (d, 1H), 7.55 (d, 1H), 7.30-7.15 (m, 7H), 7.12 (d, 2H), 6.96 (s, 1H), 6.51 (s, 1H), 4.72 (m, 3H), 3.80, 3.40 (2s, 6H), 3.28 (dd, 1H), 3.02 (dd, 1H), 2.71,
- 20 2.58, 2.12 (3s, 9H).

STEP IV


2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid.



- 5 2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid methyl ester (40 mg, 0.067 mmol) was taken in a mixture of THF:MeOH:H₂O (3:2:1) and then added 1N aqueous solution of LiOH.H₂O (0.40 mL, 0.40 mmol). The reaction mixture was stirred at room temperature for
- 10 12 h. Solvents were removed and the residue was partitioned between water and ethyl acetate. The aqueous layer was acidified using 10 % KHSO₄ solution. The organic layer was separated, dried (Na₂SO₄) and concentrated. The residue was purified by silica gel column chromatography using ethyl acetate and methanol (9:1) to
- 15 obtain 2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid. (29 mg, 75%) as a white solid. ¹H NMR (CDCl₃, 400 MHz): δ 7.59 (d, 2H), 7.48 (d, 2H), 7.42 (d, 2H), 7.19 (m, 4H), 7.06, 6.88 (2m, 6H), 6.37 (s, 1H), 4.55 (m, 3H), 3.70 (s, 3H), 3.19, 2.85 (2m, 2H), 2.56,
- 20 2.00, 1.98 (3s, 9H). ESI- (M-H): 582.

2-[(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-(4-tributylstannanyl-benzyl)-amino]-3-phenyl-propionic acid methyl ester.

5




To a stirred solution of 2-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid methyl ester (1g. 1.65mmol.) in toluene (100ml.) were added P(Ph₃)₄ Pd (123 mg., 0.107mmol.) and 1,1,1,2,2,2-Hexabutyl-distannane (1.7ml. 3.3mmol.) under nitrogen. The reaction mixture was stirred and heated to 115°C during 8 hrs. The progress of the reaction was monitored by TLC. Filtration and removal of the solvent under reduced pressure on a rotary evaporator followed by flash column chromatographic purification using 5% of EtOAc in hexane, afforded 2-[(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-(4-tributylstannanyl-benzyl)-amino]-3-phenyl-propionic acid methyl ester in 50% yield: ¹HNMR (Varian 400MHz, CDCl₃) d 7.30 (d, 2H, J=7.9Hz, HPhSn), 7.26 (m, 3H, HPh), 7.18 (d, 2H, J=7.0Hz, HPh), 7.14 (d, 2H, J=8.1Hz, HPhI), 6.53 (s, 1H, MTRH), 4.59 (m, 2H, NCH₂Ph), 3.83 (s, 3H, OCH₃), 3.26 (s, 3H, COOCH₃), 3.18(dd, 1H, J=10.5 and 13.3Hz, CHCH₂), 2.92 (dd, 1H, J=4.3 and 13.3Hz, CHCH₂), 2.69 (s, 3H, ArCH₃), 2.51 (s, 3H, ArCH₃), 2.11 (s, 3H, ArCH₃), 1.00(m, 27H, SnBu₃) ppm.

25

STEP VI

5-(4-[[(1-Methoxycarbonyl-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl]-phenyl)-thiophene-2-carboxylic acid methyl ester




5

To a stirred solution of 2-[(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-(4-tributylstannanyl-benzyl)-amino]-3-phenyl-propionic acid methyl ester (100mg. 0.13mmol.) in toluene (3ml.) were added $P(Ph_3)_4Pd$ (6mg. 0.039eq.), CuBr (2mg.) and 5-Bromo-thiophene-2-carboxylic acid methyl ester (26.5mg, 0.12mmol.) under nitrogen. The reaction mixture was stirred and heated to reflux during 5 hrs. The progress of the reaction was monitored by TLC. Filtration and removal of the solvent under reduced pressure on a rotary evaporator followed by silica plate for purification using 80% hexane 20% EtOAc afforded 5-(4-[[(1-Methoxycarbonyl-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl]-phenyl)-thiophene-2-carboxylic acid methyl ester in 41% yield: 1H NMR (Varian 400MHz, $CDCl_3$) δ 8.67(d, 1H, HPh), 8.35(d, 2H, thiopheneH), 8.10(m, 6H, HPh), 8.00(d, 2H, thiopheneH), 7.38(s, 1H, MTRH), 5.72(m, 3H, NCH_2Ph , $CHCH_2$), 4.82(s, 3H, OCH_3), 4.68(s, 3H, $COOCH_3$), 4.29(s, 3H, $COOCH_3$), 4.10(m, 1H, $CHCH_2$), 3.85(m, 1H, $CHCH_2$), 3.57(s, 3H, $ArCH_3$), 3.40(s, 3H, $ArCH_3$), 3.0(s, 3H, $ArCH_3$) ppm. MS 622.6 (M^+).

25 STEP VII

5-(4-[[[(1-Carboxy-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl]-phenyl]-furan-2-carboxylic acid



To a stirred solution of 5-(4-[[[(1-Methoxycarbonyl-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl]-phenyl]-furan-2-carboxylic acid methyl ester (16 mg, 0.026mmol.) in THF: H₂O: MeOH (3:1:2) (1ml.), was added LiOH in water (1N) (0.2ml. 0.26mmol.). The reaction mixture was stirred at room temperature during 1 hr. TLC monitored the progress of the reaction. When the reaction was completed, the mixture was concentrated under reduced pressure on a rotary evaporator. The residue was treated with a solution 20% of KHSO₄ and extracted in EtOAc. The EtOAc layer was dried over Na₂SO₄. Filtration and removal of the solvent under reduced pressure on a rotary evaporator followed by silica chromatography using 90% EtOAc, 10% MeOH and 1 drop of AcOH, afforded 5-(4-[[[(1-Carboxy-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl]-phenyl]-furan-2-carboxylic acid. ¹HNMR (Varian 400MHz, DMSO) δ 7.37 (d, 2H, J=8.5Hz, HPh), 7.27 (d, 2H, J=8.3Hz, HPh), 7.13 (m, 6H, HPh), 6.69 (d, 1H, J=3.2Hz, furanH), 6.58 (d, 1H, J=3.2Hz, furanH), 6.50 (s, 1H, MTRH), 4.81 (d, 1H, J=15.5Hz, NCH₂Ph), 4.41 (d, 1H, J=15.9Hz, NCH₂Ph), 4.06 (dd, 1H, J=3.5 and 9.5Hz, CHCH₂), 3.64 (s, 3H, OCH₃), 3.10 (dd, 1H, J=9.5 and 12.6Hz, CHCH₂), 2.65 (dd, 1H, J=3.8 and 12.6 Hz, CHCH₂), 2.49 (s, 3H, ArCH₃), 2.38 (s, 3H, ArCH₃), 1.92 (s, 3H, ArCH₃) ppm. MS 576.5 (M⁻).


The following compounds were prepared in a similar manner as described in example 2:

30


compound #5 compound #6 Compound #7 compound #8 Compound #13
 Compound #14 Compound #16 Compound #17 BCH-19067
 Compound #18 Compound #20 compound #23 compound #24 compound #26
 compound #27 compound #29 compound #32 compound #192 compound
 #193 compound #194

Example 3

2-[(2,4-dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic
 acid compound #111

STEP I

2-[(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-prop-2-ynyl-
 amino]-3-phenyl-propionic acid methyl ester




A DMF (8 mL) solution of 2-[(4-Methoxy-2,3,6-trimethyl-benzenesulfonylamino)-3-phenyl-propionic acid methyl ester
 (prepared according to example 2, step I) (200 mg) was cooled to
 0°C and then propargyl bromide (80%, 0.07 mL, 0.61 mmol) and Cs₂CO₃
 (200 mg, 0.61 mmol) were added under an atmosphere of N₂. The ice
 bath was removed and the reaction mixture was stirred at room
 temperature for 12h. The mixture was partitioned between ether and

water, the ether layer was separated, dried (Na_2SO_4) and concentrated. The residue was purified by silica gel column chromatography using ethyl acetate and hexane (1:3) as eluent to obtain 2-[(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid methyl ester (185 mg, 85%) as a solid. ^1H NMR (CDCl_3 , 400 MHz): δ 7.20-7.17 (m, 3H), 7.10-7.08 (m, 2H), 6.56 (s, 1H), 4.42-4.29 (m, 3H), 3.86 (s, 3H), 3.56 (s, 3H), 3.32 (dd, 1H), 3.26 (dd, 1H), 2.66, 2.35 (2s, 6H), 2.21 (t, 1H), 2.08 (s, 3H).

STEP II


3-Phenyl-2-prop-2-ynylamino-propionic acid methyl ester



To a solution of 2-[(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid methyl ester (150 mg, 0.349 mmol) in anhydrous dichloroethane (1.5 mL), trifluoroacetic acid (3.5 mL) and ethyl methyl sulfide (0.16 mL, 1.75 mmol) were added. The reaction mixture was stirred at room temperature under a N_2 atmosphere for 12h. Excess of solvents were removed under reduced pressure and the residue was extracted between saturated NaHCO_3 solution and ethyl acetate. The organic layer was separated, dried (Na_2SO_4), concentrated. The crude product was purified by silica gel column chromatography using ethyl acetate and hexane (1:3) as eluent to obtain 3-Phenyl-2-prop-2-ynylamino-propionic acid methyl ester as a thick syrup, 70 mg (92%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.32-7.19 (m, 5H), 3.78 (t, 1H), 3.68 (s, 3H), 3.40 (ABq, 2H), 3.03 (dd, 1H), 2.98 (dd, 1H), 1.99 (t, 1H).

STEP III

2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid methyl ester




5

A solution of 3-Phenyl-2-prop-2-ynylamino-propionic acid methyl ester (75 mg, 0.346 mmol) in anhydrous CH_2Cl_2 (2 mL) was cooled to 0°C in an ice bath, then triethylamine (0.1 mL) and 2,4-dichlorobenzoyl chloride (0.06 mL, 0.45 mmol) were added. The mixture was stirred at room temperature for 3h. Excess of benzoyl chloride was quenched by adding ice-cold water and then the reaction mixture was partitioned between water and CH_2Cl_2 . The organic layer was separated, dried (Na_2SO_4), and concentrated. The residue was purified by silica gel column chromatography using ethyl acetate and hexane (1:3) as eluent to obtain 2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid methyl ester as a syrup, 125 mg (93%).

STEP IV

2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid



To a THF:MeOH:H₂O (3:2:1) (3 mL) solution of 2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid methyl ester (30 mg, 0.076 mmol), 1N aqueous solution of lithium hydroxide (0.46 mL, 0.46 mmol) was added and the reaction mixture was stirred at room temperature for 6h. Solvents were removed under


reduced pressure and the residue was partitioned between ethyl acetate and water. The water layer was acidified using 10% KHSO₄ solution and then the organic layer was separated, dried (Na₂SO₄), concentrated. The residue was purified by column chromatography (ethyl acetate:hexane 1:1 to ethyl acetate) to obtain 2-[(2,4-dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid, 23 mg (81%) as a white solid. The compound contains two other minor rotamers. ¹H NMR (CDCl₃, 400 MHz): δ 7.45-7.05 (m, 8H), 6.77 (dd, minor rotamer), 5.70 (d, minor rotamer), 4.99 (bs, minor rotamer), 4.64-4.59 (m, minor rotamer), 4.28 (d, minor rotamer), 4.29-4.18 (m, minor rotamer), 3.79-3.09 (m, 5H), 2.37 (t, minor rotamer), 2.31 (t, minor rotamer), 2.17 (t, 1H). ESI⁻ (M-H): 375.

The following compounds were prepared in a similar manner as described in example 3:

compound #109
 compound #110
 compound #111
 compound #112
 compound #115
 compound #116

Example 4

2-[(3-Benzofuran-2-yl-prop-2-ynyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #113




To a solution of 2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid methyl ester (prepared according to example 9) (50 mg, 0.128 mmol) and 2-iodobenzofuran (41 mg, 0.166 mmol) in DMF (2 mL), triethylamine (2 mL) and tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.01 mmol) were added and the reaction mixture was stirred under reflux conditions

- for 4h under a N₂ atmosphere. DMF and triethylamine were removed under reduced pressure and the residue was partitioned between water and ethyl acetate. The organic layer was separated, dried (Na₂SO₄), concentrated and the residue was purified by column chromatography using ethyl acetate and hexane (1:4) as eluent to obtain 2-[(3-Benzofuran-2-yl-prop-2-ynyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid methyl ester as a thick syrup, 50 mg (76%). The compound contains two other rotamers. ¹H-NMR (CDCl₃, 300 MHz): δ 7.58-7.09 (m, 12H), 6.98 (s, minor rotamer), 6.97 (d, minor rotamer), 6.85 (dd, minor rotamer), 6.83 (s, 1H), 5.82 (d, minor rotamer), 5.25 (bs, minor rotamer), 5.10 (bs, minor rotamer), 4.88-4.52 (m, minor rotamer), 4.35-3.21 (m, 5H), 3.78 (s, 3H), 3.76, 3.65 (2s, minor rotamer).
- A procedure similar to step IV (example 9) was used for the hydrolysis of 2-[(3-Benzofuran-2-yl-prop-2-ynyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid methyl ester. 2-[(3-Benzofuran-2-yl-prop-2-ynyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid was isolated after silica gel column chromatography using ethyl acetate:hexane (1:1) to ethyl acetate as eluent as a solid, 20 mg (69%). The compound contains two other rotamers. ¹H-NMR (CDCl₃, 400 MHz): ? 7.82 (d, minor rotamer), 7.53-7.05 (m, 12H), 6.93 (s, minor rotamer), 6.89 (d, minor rotamer), 6.81 (s, 1H), 6.80 (dd, minor rotamer), 6.49 (m, minor rotamer), 6.26 (d, minor rotamer), 5.73 (d, minor rotamer), 5.22 (bs, minor rotamer), 5.09-4.45 (m, minor rotamers), 4.36-3.11 (m, 5H). ESI⁻ (M-H): 491.

Example 5


2-[(4-Benzofuran-2-yl-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid compound #114



5

STEP I

2-(4-Bromo-phenylamino)-3-phenyl-propionic acid *tert*-butyl ester




10

A mixture of L-phenylalanine *tert*-butyl ester (1.47 g, 6.64 mmol), 4-bromophenylboronic acid (2.67 g, 13.28 mmol), triethylamine (1.9 mL, 13.28 mmol) and copper (II) acetate (1.21 g, 6.64 mmol) in dichloromethane (50 mL) was stirred at room temperature for 24 h. The solids were removed by filtration through a pad of silica gel and the desired product was obtained by chromatography eluting with 5% ethyl acetate in hexanes. ¹H NMR (CDCl₃) 7.2 (m, 8 H), 6.48 (d, 2 H), 4.18 (t, 2 H, H-2 and NH), 3.08 (d, 2 H), 1.35 (s, 9 H)

STEP II

2-[(4-Bromo-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid tert-butyl ester




5

This compound was prepared in a similar manner as for step I in example 1. ^1H NMR (CDCl_3) 7.2 (m,), 7.2 (d), 7.0 (d, 6.93 (d), 6.4 br s), 4.62 (t, 1 H), 3.4 9m, 2 H), 1.3 (s, 9 H)

10 STEP III


2-[(4-Benzofuran-2-yl-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid tert-butyl ester



15 This compound was prepared in a similar manner as for step III in example 2. ^1H NMR (CDCl_3) 7.6 (m), 7.3 (m), 6.9 (m), 6.7 (m), 4.8 (m), 4.2 (m), 3.5 (m)

STEP IV

20 2-[(4-Benzofuran-2-yl-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid



This compound was prepared in a similar manner as for step IV in example 1. ¹H NMR (DMSO) 13.1 (br s, 1 H), 7.6 (m, 5 H), 7.3 (m, 9 H), 7.01 (d, 2 H), 6.72 (d, 2 H), 4.95 (dd, 1 H), 3.39 (2
5 H)

The following compounds were prepared in a similar manner as described in example 5:

Compound 190 Compound 191

10 Example 5 The following compound was obtained from Oxford Diversity:






Compound #1,






15 The following compounds were prepared as listed in Table 1 and Table 2.

TABLE 1. LIST OF COMPOUNDS HAVING POLYMERASE ACTIVITY

Compound #	Compound Name	Structure	RNA pol Assay 1	RNA pol Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #1	3-[3-(2,6-Dichloro-pyridin-4-yl)-1-(4-thiophen-2-yl-benzyl)-ureido]-3-thiophen-2-yl-propionic acid		++	
compound #2	(2S)-2-[(2,4-Dichloro-benzoyl)-(4-thiazol-2-yl-benzyl)-amino]-3-phenyl-propionic acid,		+++	
compound #3	(2S)-2-[(4-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid,		+++	






Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #4	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid,		+++	
compound #5	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid,		+++	
compound #6	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid,		+++	
compound #7	(2S)-2-[(3-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #7		+++	
compound #8	3-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-thiophen-2-yl-propionic acid ethyl ester,		++	






Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #9	(2S)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid,		+++	
compound #10	(2S)-2-[(3-Bromo-benzyl)-(2-chloro-benzoyl)-amino]-3-phenyl-propionic acid,		+	
compound #11	(2S)-2-[(3-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid,		++	
compound #12	(2S)-2-[(2,4-Dichloro-benzoyl)-(4-iodo-benzyl)-amino]-3-phenyl-propionic acid,	 Chiral	++	
compound #13	(2S)-2-[(3-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid,		++	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #14	(2S)-2-[(4-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid,		++	
compound #15	(2S)-2-[(3-Bromo-benzyl)-(4-chloro-benzoyl)-amino]-3-phenyl-propionic acid;		Chiral ++	
compound #16	(2S)-2-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid		Chiral ++	
compound #17	(2S)-2-[(3-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid		Chiral ++	
compound #18	(2S)-5-(4-([1S]-1-Carboxy-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino)-methyl-phenyl)-furan-2-carboxylic acid methyl ester		+	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC_{50} (μ m)	RNA pol Assay 2 IC_{50} (μ m)
compound #19	(2s)-2-[(3-Bromo-benzyl)-(3,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+	
compound #20	(2s)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzenesulfonyl)-amino]-3-phenyl-propionic acid		+	
compound # 21	(2s)-3-(1-Benzyl-1h-imidazol-4-yl)-2-[(3-bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-propionic acid		++	
compound #22	(2s)-2-[(3-Bromo-benzyl)-[(2,4-dichloro-phenyl)-acetyl]-amino]-3-phenyl-propionic acid		++	
compound #23	(2s)-5-(4-[(1s-1-Carboxy-2-phenylethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl)-phenyl)-thiophene-2-carboxylic acid methyl ester		+	

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #24	(2s)-2-[(2-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid		++	
compound #25	(2s)-2-[(3-Bromo-benzyl)-(4-chloro-phenoxy-carbonyl)-amino]-3-phenyl-propionic acid		+	
compound #26	(2s)-Triethyl-ammonium; 2-[(3-benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionate		+++	
Compound #27	2-[Allyl-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid		++	
compound #28	(2s)-2-[(3-Bromo-benzyl)-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid		+++	
Compound #29	3-(4-Benzofuran-2-yl-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid			++

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #30	(2S)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzyl)-amino]-3-phenyl-propionic acid		Chiral +++	
compound #31	(2S)-2-[(3-Benzofuran-2-yl-benzyl)-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid		Chiral +++	
compound #32	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid		+++	
compound #33	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid		+++	
compound #34	(2S)-2-[(3-Bromo-benzyl)-(4-chloro-2-methyl-benzoyl)-amino]-3-phenyl-propionic acid		Chiral +++	







Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #35	(2S)-2-[(3-Bromo-benzyl)-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid		Chiral +++	
compound #36	(2S)-2-[(3-Bromo-benzyl)-(2-bromo-4-chloro-benzoyl)-amino]-3-phenyl-propionic acid		Chiral +++	
compound #37	(2S)-2-[(3-Benzofuran-2-yl-benzyl)-[(2,4-dichloro-phenyl)-acetyl]-amino]-3-phenyl-propionic acid		Chiral +++	
compound #38	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-phenyl)-amino]-3-phenyl-propionic acid		+++	
compound #39	(2S)-2-[(2,4-Dichloro-benzoyl)-naphthalen-2-ylmethyl-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #40	(2S)-2-[(2,4-Dichloro-benzoyl)-(9,10-dioxo-9,10-dihydro-anthracen-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #41	(2S)-2-[[3-(3-Chloro-benzoyl)-benzyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #42	(2S)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-difluoro-benzoyl)-benzyl]-amino]-3-phenyl-propionic acid		+++	
compound #43	(2S)-2-[[3-[3-(2-Chloro-phenyl)-5-methyl-isoxazole-4-carbonyl]-benzyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #44	(2S)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-dichloro-benzoyl)-benzyl]-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #45	(2S)-2-[(3-Benzooxazol-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #46	(2S)-2-[(3-Bromo-benzyl)-(4-chloro-2-ethyl-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #47	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-cyclohexyl-propionic acid		+++	
compound #48	(2S)-2-[(3-Benzofuran-2-yl-benzyl)-(4-chloro-2-methyl-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #49	(2S)-2-[(3-Benzofuran-2-yl-benzyl)-(2-bromo-4-chloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #50	(2S)-2-[(3-Bromo-benzyl)-(4-chloro-2-vinyl-benzoyl)-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #51	(2S)-2-[(2,4-Dichloro-benzoyl)-(3-fluoro-benzyl)-amino]-3-phenyl-propionic acid		+++	
compound #52	(2S)-2-[(3-Chloro-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
Compound #53	(2S)-2-[(2,4-Dichloro-benzoyl)-(3-nitro-benzyl)-amino]-3-phenyl-propionic acid,			+++
compound #54	(2S)-2-[(3-Cyano-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			+++
compound #55	(2S)-2-[(2-Chloro-benzoyl)-[5-(3-chloro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		++	
compound #56	(2S)-2-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #57	(2S)-2-[(5-Bromo-furan-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		++	
compound #58	(2S)-2-[(5-Benzofuran-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #59	(2S)-2-[[5-(4-Bromo-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #60	(2S)-2-[[5-(2-Chloro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #61	(2S)-2-[[5-(2-Chloro-5-trifluoromethyl-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #62	(2S)-2-[(2,4-Dichloro-benzoyl)-[5-(2-nitro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	






Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1 IC ₅₀ (μm)	Assay 2 IC ₅₀ (μm)
compound #63	(3s)-3-((2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-4-phenyl-butyric acid		+++	
compound #64	2-((2,4-Dichloro-benzoyl)-[2-(3-nitro-phenyl)-thiazol-5-ylmethyl]-amino)-3-phenyl-propionic acid			+++
compound #65	(2s)-2-((2,4-Dichloro-benzoyl)-[5-(3,4-dichloro-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid		+++	
compound #66	(2s)-2-[Benzofuran-2-ylmethyl-(2,4-dichloro-benzyl)-amino]-3-phenyl-propionic acid		+++	
compound #67	(2s)-2-((2,4-Dichloro-benzoyl)-[5-(2,4-dichloro-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid		+++	
compound #68	(2s)-2-[(2-Bromo-4-chloro-benzoyl)-(5-bromo-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #69	(2S)-2-[[5-(3-Chloro-4-fluorophenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #70	(2S)-2-[[5-(4-Chloro-3-fluorophenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #71	(2S)-2-[(5-Bromo-furan-2-ylmethyl)-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #72	(2S)-2-(5-[(1S-1-Carboxy-2-phenylethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-furan-2-yl)-benzoic acid ethyl ester		+++	
compound #73	(2S)-2-(5-[(1-Carboxy-2-phenylethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-furan-2-yl)-benzoic acid		+++	

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #74	(2S)-2-[(2,4-Dichloro-benzoyl)-(5-thiazol-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #75	(2S)-2-[(2,4-Dichloro-benzoyl)-furan-2-ylmethyl-amino]-3-phenyl-propionic acid		++	
compound #76	(2S)-3-(5-[(1S-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-furan-2-yl)-benzoic acid		+++	
compound #77	(2S)-4-(5-[(1S-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-furan-2-yl)-benzoic acid		+++	
compound #78	(2S)-2-[(2-Bromo-4-chloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #79	(2S)-2-[(2,4-Dichloro-benzoyl)-[5-(3,5-difluorophenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #80	(2S)-2-[(2,4-Dichloro-benzoyl)-[5- <i>m</i> -tolyl-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #81	(2S)-2-[(2,4-Dichloro-benzoyl)-[5-(3-fluorophenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #82	(2S)-2-[(5-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #83	(2S)-4-(5-[(1S-1-Carboxy-2-phenylethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-2-yl)-benzoic acid		+++	
compound #84	(2S)-4-(5-[(1S-1-Carboxy-2-phenylethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-2-yl)-benzoic acid methyl ester		+++	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #85	(2S)-2-[(5-Benzofuran-2-yl-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #86	2-[(2-Benzofuran-2-yl-thiazol-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			+++
compound #87	(2S)-2-[(2,4-Dichloro-benzoyl)-[4-(3,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #88	(2S)-2-[[4-(4-Chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #89	(2S)-2-[[4-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid,		+++	
compound #90	(2S)-2-[(2,4-Dichloro-benzoyl)-[4-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #91	(2s)-2-[[5-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #92	(2s)-2-[[5-(4-chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #93	(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #94	(2s)-2-[(2,4-Dichloro-benzoyl)-(5-thiazol-2-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #95	(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #96	(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #97	(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #98	(2s)-2-[(2,4-Dichloro-benzoyl)-thiophen-2-ylmethyl-amino]-3-phenyl-propionic acid		+++	
compound #99	(2s)-2-[(4-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #100	(2s)-2-[(2,4-Dichloro-benzoyl)-[2-(4-phenyl-piperazin-1-yl)-thiazol-5-ylmethyl]-amino]-3-phenyl-propionic acid		++	
compound #101	(2s)-1-(5-[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiazol-2-yl)-piperidine-4-carboxylic acid		++	






Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #102	(2s)-2-[[2-(4-Benzyl-piperazin-1-yl)-thiazol-5-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #103	(2s)-2-[(2,4-Dichloro-benzoyl)-(2-piperidin-1-yl-thiazol-5-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #104	(2s)-2-[(2,4-Dichloro-benzoyl)-(2-diethylamino-thiazol-5-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #105	(2s)-2-[[2-(4-Chloro-benzoyl)-benzofuran-3-ylmethyl]-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid		++	
compound #106	(2s)-2-[[5-(2,4-Dichloro-phenoxy)-1-methyl-3-trifluoromethyl-4-pyrazol-ylmethyl]-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid		++	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #107	(2s)-2-((2,4-Dichloro-benzoyl)-(2-[5-(2,4-dichloro-phenyl)-furan-2-yl]-2-oxo-ethyl)-amino)-3-phenyl-propionic acid		+++	
compound #108	(2s)-2-Benzyl-4-(2,4-dichloro-phenyl)-3-[3-(2,6-dichloro-phenyl)-5-methyl-isoxazol-4-ylmethyl]-4-oxo-butyric acid		+++	
compound #109	(2s)-2-[Allyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		++	
compound #110	(2s)-2-[(2,4-Dichloro-benzoyl)-methyl-amino]-3-phenyl-propionic acid		++	
compound #111	(2s)-2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid		++	
compound #112	(2s)-2-[(2,4-Dichloro-benzoyl)-propyl-amino]-3-phenyl-propionic acid		+	

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #113	(2 <i>S</i>)-2-[(3-Benzofuran-2-yl-prop-2-ynyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #114	(2 <i>S</i>)-2-[(4-Benzofuran-2-yl-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #115	(2 <i>S</i>)-2-[(2,4-Dichloro-benzoyl)-(3-methyl-but-2-enyl)-amino]-3-phenyl-propionic acid		++	
compound #116	2-[(2-Bromo-allyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		++	
Compound #117	3-[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl-benzoic acid methyl ester			+++
Compound #118	3-[[5-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-5-phenyl-thiophene-2-carboxylic acid			+++

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1 IC ₅₀ (μm)	Assay 2 IC ₅₀ (μm)
Compound #119	2-[[5-(3-Cyano-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			+++
compound #120	(2s)-2-((2,4-Dichloro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid,		+++	
compound #121	(2s)-2-(5-((1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino)-methyl)-thiophen-2-yl)-benzoic acid ethyl ester		+++	
compound #122	3-(5-((1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino)-methyl)-thiophen-2-yl)-benzoic acid ethyl ester		+++	
compound #123	(2s)-2-[[5-(3-Chloro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #124	(2s)-2-[(4-Chloro-2-iodo-benzoyl)-(3,5-dibromo-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA 5G	RNA pol
			Assay 1 <u>IC₅₀</u> (μ m)	Assay 2 <u>IC₅₀</u> (μ m)
compound #125	(2s)-3-(5-([(1-Carboxy-2-phenylethyl)-(2,4-dichlorobenzoyl)-amino]-methyl)-thiophen-2-yl)-benzoic acid		+++	
compound #126	(2s)-2-[[5-(5-Chloro-thiophen-2-yl)-furan-2-ylmethyl]-(2,4-dichlorobenzoyl)-amino]-3-phenylpropionic acid		+++	
compound #127	(2s)-2-[[[2,2']Bithiophenyl-5-ylmethyl]-(2,4-dichlorobenzoyl)-amino]-3-phenylpropionic acid		+++	
compound #128	(2s)-2-[[5'-(5-Chloro-[2,2']bithiophenyl-5-ylmethyl)thiophen-2-ylmethyl]-(2,4-dichlorobenzoyl)-amino]-3-phenylpropionic acid		+++	
compound #129	(2s)-2-[(2,4-Dichlorobenzoyl)-[4-(3,5-difluorophenyl)-thiophen-2-ylmethyl]-amino]-3-phenylpropionic acid		+++	
compound #130	(2s)-2-[(2,4-Dichlorobenzoyl)-[4-(3-fluorophenyl)-thiophen-2-ylmethyl]-amino]-3-phenylpropionic acid		+++	






Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #131	(2s)-2-((4-Chloro-2-iodo-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid		+++	
compound #132	(2s)-2-((4-Chloro-2-methyl-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid		+++	
compound #133	(2s)-2-[(5-Chloro-[2,3']bithiophenyl-5'-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		+++	
compound #134	(2s)-2-((2,4-Dichloro-benzoyl)-[5-(4-methoxy-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid		+++	
compound #135	(2s)-2-((2,4-Dichloro-benzoyl)-[5-(4-methoxy-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid		+++	

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #136	(2S)-2-[(2,4-Dichloro-benzoyl)-[4-(4-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	
compound #137	(2S)-2-[(2,4-Dichloro-benzoyl)-(5-pyridin-4-yl-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #138	(2S)-2-[(2,4-Dichloro-benzoyl)-(5-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #139	(2S)-2-[(2,4-Dichloro-benzoyl)-(4-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid		+++	
compound #140	(2S)-2-[(2-Chloro-thiazol-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			+++

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #141	(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(4-fluorophenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			+++
compound #142	(2s)-2-[(2,4-Dichloro-benzoyl)-(3,5-dichlorobenzyl)-amino]-3-phenyl-propionic acid			+++
compound #143	(2s)-2-[(2,4-Dichloro-benzoyl)-thiophen-3-ylmethyl-amino]-3-phenyl-propionic acid			+++
compound #144	(2s)-2-[(2,4-Dichloro-benzoyl)-(3-trifluoromethylbenzyl)-amino]-3-phenyl-propionic acid			+++
compound #145	(2s)-2-[[3-(3-Chloro-4-fluorophenyl)-thiophen-2-ylmethyl]- (2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1 IC_{50} (μ m)	Assay 2 IC_{50} (μ m)
compound #146	(2S)-2-[(3-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			+++
compound #147	(2S)-2-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-2-methyl-propionic acid			++
compound #148	(2S)-2-[(2,4-Dichloro-benzoyl)-[2-(3-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-amino]-3-phenyl-propionic acid			+++
compound #149	(2S)-2-[(2,4-Dichloro-benzoyl)-(5-nitro-thiophen-3-ylmethyl)-amino]-3-phenyl-propionic acid			+++
compound #150	(2S)-2-[(2,4-Dichloro-benzoyl)-(4-methanesulfonyl-benzyl)-amino]-3-phenyl-propionic acid			+++






Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #151	(2S)-2-[(2,4-Dichloro-benzoyl)-(3-methoxy-benzyl)-amino]-3-phenyl-propionic acid			+++
compound #152	(2S)-2-[(2,4-Dichloro-benzoyl)-(3-methyl-benzyl)-amino]-3-phenyl-propionic acid			+++
compound #153	(2S)-2-[[5-(3-Chloro-phenoxy)-1-methyl-3-trifluoromethyl-1h-pyrazol-4-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++
compound #154	(2S)-2-[(2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			+++
compound #155	(2S)-2-[(2,4-Dichloro-benzoyl)-[3-(3,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			+++
compound #156	(2S)-2-[[3-(4-Chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #157	(2 <i>S</i>)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			++
compound #158	(2 <i>S</i>)-2-[(2,4-Dichloro-benzoyl)-(3- <i>m</i> -tolyl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid			+++
compound #159	(2 <i>S</i>)-2-(2-[(1 <i>S</i> -1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-3-yl)-benzoic acid ethyl ester			++
compound #160	(2 <i>S</i>)-4-(2-[(1 <i>S</i> -1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-3-yl)-benzoic acid ethyl ester			+++
compound #161	(2 <i>S</i>)-2-[(2,4-Dichloro-benzoyl)-[3-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			++






Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
compound #162	(2S)-2-[[3-(3-Cyano-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			+++
compound #163	((2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-thiophen-2-yl-acetic acid			++
compound #164	L-2-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-pyrrolidine-1-carboxylic acid #tert!-butyl ester		Chiral	++
compound #165	d-2-[[1-(1-carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-pyrrolidine-1-carboxylic acid #tert!-butyl ester		Chiral	++
compound #166	4-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-piperidine-1-carboxylic acid benzyl ester		Chiral	++

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1 IC ₅₀ (μm)	Assay 2 IC ₅₀ (μm)
compound #167	1-2-[(2,4-Dichloro-benzoyl)-pyrrolidin-2-ylmethyl-amino]-3-phenyl-propionic acid		Chiral	++
compound #168	d-2-[(2,4-Dichloro-benzoyl)-pyrrolidin-2-ylmethyl-amino]-3-phenyl-propionic acid		Chiral	++
compound #169	3-(5-Bromo-thiophen-2-yl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid			+++
compound #170	2-[(2,4-Dichloro-benzoyl)-pyridin-3-ylmethyl-amino]-3-phenyl-propionic acid			++
compound #171	2-[(2,4-Dichloro-benzoyl)-(4-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid			++

Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #172	2-[(2,4-Dichloro-benzoyl)-(4-(4-fluoro-benzyloxy)-benzyl)-amino]-3-phenyl-propionic acid			++
compound #173	2-[(2,4-Dichloro-benzoyl)-(4-fluoro-3-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid			++
compound #174	2-[(1-Benzenesulfonyl-1h-pyrrol-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++
compound #175	2-[[3-(4-Chloro-phenoxy)-benzyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++







Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #176	2-[(5-Chloro-2-chloromethyl-hepta-2,4,6-trienoyl)-quinolin-3-ylmethyl-amino]-3-phenyl-propionic acid			++
compound #177	2-[(2-Benzyloxy-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++
compound #178	2-[(2,4-Dichloro-benzoyl)-[3-(5-isopropyl-2-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			++
compound #179	2-[(2,4-Dichloro-benzoyl)-[3-(4-trifluoromethoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			++
compound #180	2-[(2,4-Dichloro-benzoyl)-[3-(3-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			++


Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
compound #181	2-[[3-(3,5-Bis-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]- (2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++
compound #182	2-[(2,4-Dichloro-benzoyl)-(3-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid			++
compound #183	2-[(2,4-Dichloro-benzoyl)-[3-(4-methylsulfanyl-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			++
compound #184	2-[(2,4-Dichloro-benzoyl)-[3-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid			+++
compound #185	2-[(2,4-Dichloro-benzoyl)-(3-pyridin-3-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid			+++

Compound #	Compound Name	Structure	RNA pol Assay 1 <u>IC₅₀</u> (μm)	RNA pol Assay 2 <u>IC₅₀</u> (μm)
compound #186	2-[(2,4-Dichloro-benzoyl)-[1-(toluene-2-sulfonyl)-pyrrolidin-2-ylmethyl]-amino]-3-phenyl-propionic acid			
compound #187	2-[(2-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++
compound #188	3-(2-Bromo-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid			++
compound #189	3-(4-Bromo-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid			+++
compound #190	2-[(3-Bromo-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++ flashplate

Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1 IC_{50} (μ m)	Assay 2 IC_{50} (μ m)
Compound #191	2-[(4-Bromo-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			+
Compound #192	2-[[4-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid			+++
Compound #193	3-[[[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid			+++
Compound #194	2-[(3-Amino-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++
Compound #199	2-[Benzyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid			++




Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
Compound #200	2-[(2,4-DICHLORO-BENZOYL)-[3-(2H-TETRAZOL-5-YL)-BENZYL]-AMINO]-3-PHENYL-PROPIONIC ACID			+++
Compound #201	2-[(2,4-DICHLORO-BENZOYL)-(2-NITRO-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID			++
Compound #202	2-[(2,4-DICHLORO-BENZOYL)-(4-NITRO-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID			++
Compound #203	2-[(2-CYANO-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID			++
Compound #204	2-[(4-CYANO-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID			++






Compound #	Compound Name	Structure	RNA pol	RNA pol
			Assay 1	Assay 2
			IC ₅₀ (μm)	IC ₅₀ (μm)
Compound #205	2-[[1-(3-CYANO-PHENYL)-ETHYL]-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID			++
Compound #206	3-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid methyl ester			+++
Compound #207	3-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid			+++
Compound #208	2-[(2,4-DICHLORO-BENZOYL)-(3-METHANESULFONYL-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID			++
Compound #209	2-[(3-ACETYL-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID			+++
Compound #210	2-[(2,4-DICHLORO-BENZOYL)-(1-OXY-PYRIDIN-3-YLMETHYL)-AMINO]-3-PHENYL-PROPIONIC ACID			+++


Compound #	Compound Name	Structure	RNA pol Assay 1 IC ₅₀ (μm)	RNA pol Assay 2 IC ₅₀ (μm)
Compound #211	2-((2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-amino)-3-phenyl-propionic acid			++

*: +++ IC₅₀ <5μm
 ++ IC₅₀ 5μm-20μm
 + IC₅₀ >20μm

5 TABLE 2. LIST OF COMPOUNDS HAVING ANTI-HELICASE ACTIVITY

Compound #	Compound name	Structure	Anti-ATPase activity (Malachite Green assay) EC ₅₀ (μm)	Anti-ATPase activity (HPLC method) EC ₅₀ (μm)
Compound #4	(2S)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid,		++	++
Compound #11	(2S)-2-[(3-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid,		+++	++
Compound #85	2-[(5-Benzofuran-2-yl-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid		++	++

Compound #5	(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid,		++	++
Compound #7	(2s)-2-[(3-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #7		++	+
Compound #195	3-Phenyl-2-[(2-trifluoromethyl-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-propionic acid		++	++
Compound #196	2-[(3-Cyano-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	+++
Compound #197	2-[(4-Nitro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid		+++	+++

Compound #198	2-((2-Fluoro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino)-3-phenyl-propionic acid		+++	++
------------------	--	---	-----	----

*: +++ IC₅₀ <5μM
 ++ IC₅₀ 5μM-20μM
 + IC₅₀ >20μM

5 Example 6 Evaluation of Biaryl Analogues in The HCV RNA-Dependent RNA Polymerase Assay

The following references are all incorporated by reference:

1. Behrens, S., Tomei, L., De Francesco, R. (1996) *EMBO* 15, 12-22
2. Harlow, E, and Lane, D. (1988) *Antibodies: A Laboratory Manual*. Cold Spring Harbord Laboratory. Cold Spring Harbord. NY.
3. Lohmann, V., Körner, F., Herian, U., and Bartenschlager, R. (1997) *J. Virol.* 71, 8416-8428
4. Tomei, L., Failla, C., Santolini, E., De Francesco, R., and La Monica, N. (1993) *J Virol* 67, 4017-4026

Compounds were evaluated using an *in vitro* polymerase assay containing purified recombinant HCV RNA-dependent RNA polymerase (NS5B protein). HCV NS5B was expressed in sf9 insect cells using a recombinant baculovirus as vector. The experimental procedures used for the cloning, expression and purification of the HCV NS5B protein are described below. Follows, are details of the RNA-dependent RNA polymerase assays used to test the compounds.

The cDNA encoding the entire NS5B protein of HCV-Bk strain, genotype 1b, was amplified by PCR using the primers NS5Nhe5' (5'-GCTAGCGCTAGCTCAATGTCCTACACATGG-3') and XhoNS53' (5'-CTCGAGCTCGAGCGTCCATCGGTTGGGGAG-3') and the plasmid pCD 3.8-9.4 as template (Tomei et al, 1993). NS5Nhe5' and XhoNS53' contain

two *NheI* and *XhoI* sites (underlined sequences), respectively, at their 5' end. The amplified DNA fragment was cloned in the bacterial expression plasmid pET-21b (Novagen) between the restriction sites *NheI* and *XhoI*, to generate the plasmid pET/NS5B. This plasmid was later used as template to PCR-amplify the NS5B coding region, using the primers NS5B-H9 (5'-ATACATATGGCTAGCATGTCAATGTCCTACACATGG-3') and NS5B-R4 (5'-GGATCCGGATCCCGTTCATCGGTTGGGGAG-3'). NS5B-H9 spans a region of 15 nucleotides in the plasmid pET-21b followed by the translation initiation codon (ATG) and 8 nucleotides corresponding to the 5' end of the NS5B coding region (nt. 7590-7607 in the HCV sequence with the accession number M58335). NS5B-R4 contains two *BamHI* sites (underlined) followed by 18 nucleotides corresponding to the region around the stop codon in the HCV genome (nt. 9365-9347). The amplified sequence, of 1.8 kb, was digested with *NheI* and *BamHI* and ligated to a predigested pBlueBacII plasmid (Invitrogen). The resulting recombinant plasmid was designated pBac/NS5B. Sf9 cells were co-transfected with 3 µg of pBac/NS5B, together with 1 µg of linearized baculovirus DNA (Invitrogen), as described in the manufacturer's protocol. Following two rounds of plaque purification, an NS5B-recombinant baculovirus, BacNS5B, was isolated. The presence of the recombinant NS5B protein was determined by western blot analysis (Harlow and Lane, 1988) of BacNS5B-infected Sf9 cells, using a rabbit polyclonal antiserum (anti-NS5B) raised against a His-tagged version of the NS5B protein expressed in *E. coli*. Infections of Sf9 cells with this plaque purified virus were performed in one-liter spinner flasks at a cell density of 1.2×10^6 cells/ml and a multiplicity of infection of 5.

Sf9 cells were infected as described above. Sixty hours post-infection, cells were harvested then washed twice with phosphate buffer saline (PBS). Total proteins were solubilized as described in Lohmann *et al.* (1997) with some modifications. In brief, proteins were extracted in three steps, S1, S2, S3, using lysis buffers (LB) I, LB II and LB III (Lohmann *et al.*, 1997). The composition of LBII was modified to contain 0.1 % triton X-100 and 150 mM NaCl to reduce the amount of solubilized NS5B

protein at this step. In addition, sonication of cell extracts was avoided throughout the protocol to preserve the integrity of the protein structure.

5 Purification of recombinant NS5B using fast protein liquid chromatography (FPLC):

Soluble NS5B protein in the S3 fraction was diluted to lower the NaCl concentration to 300 mM, then it incubated batchwise with DEAE sepharose beads (Amersham-Pharmacia) for 2 hrs at 4°C, as
10 described by Behrens et al. (1996). Unbound material was cleared by centrifugation for 15 min at 4°C, at 25 000 rpm using a SW41 rotor (Beckman). The supernatant was further diluted to lower the NaCl concentration to 200 mM and subsequently loaded, with a flow rate of 1 ml/min, on a 5 ml HiTrap® heparin column
15 (Amersham-Pharmacia) connected to an FPLC® system (Amersham-Pharmacia). Bound proteins were eluted in 1 ml fractions, using a continuous NaCl gradient of 0.2 to 1 M, over a 25 ml volume. NS5B-containing fractions were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed
20 by western blotting using the anti-NS5B antiserum at a dilution of 1:2000. Positive fractions were pooled and the elution buffer was exchanged against a 50 mM NaPO₄ pH 7.0, 20 % glycerol, 0.5 % triton X-100 and 10 mM DTT, using a PD-10 column (Amersham-Pharmacia). The sample was then loaded onto a 1 ml
25 HiTrap® SP column (Amersham-Pharmacia), with a flow rate of 0.1 ml/min. Bound proteins were eluted using a continuous 0 to 1 M NaCl gradient over a 15 ml volume. Eluted fractions were analyzed by SDS-PAGE and western blotting. Alternatively, proteins were visualized, following SDS-PAGE, by silver staining
30 using the Silver Stain Plus kit (BioRad) as described by the manufacturer. Positive fractions were tested for RdRp activity (see below) and the most active ones were pooled, and stored as a 40 % glycerol solution at -70°C.

35 In vitro RNA-dependent RNA polymerase assays used to evaluate biaryl analogues (Assay 1):

RdRp assays were conducted using the homopolymeric template/primer polyA/oligo dT. All RdRp reactions were

performed in a total volume of 50 μ l, and in a basic buffer consisting of 20 mM Tris-HCl pH 7.5, 1mM DTT, 50 mM NaCl, 5 mM MgCl₂, 0.5 μ Ci [γ ³²P]-UTP (3000 Ci/mmol), 15 μ M cold UTP and 20 U RNasin (Promega). Standard HCV RdRp reactions contained 200 ng of purified NS5B protein. PolyA RNAs (Amersham-Pharmacia) was resuspended at 400 ng/ μ l. The primer oligodT₁₅ (Canadian life technologies) was diluted to a concentration of 20 pmol/ml (7.6 ng/ μ l). Templates and primers were mixed volume to volume, denatured at 95°C for 5 min and annealed at 37°C for 10 min.

Following a two hour incubation at 22°C, reactions were stopped by the addition of 100 μ g of sonicated salmon sperm DNA (Life Technologies) and 1 ml of 10 % trichloroacetic acid-0.5 % tetrasodium pyrophosphate (TCA-PPi). Nucleic acids were precipitated at 4°C for 30 min after which samples were filtered on GF/C glass microfiber filters (Millipore). Membranes were subsequently washed with 25 ml of a 1% TCA-0.1 % PPi solution, then air dried. Incorporated radioactivity was quantified using a liquid scintillation counter (1450-Microbeta, Wallac). Results are shown in Table 1, in the column indicated as Assay 1..

20

In vitro HCV RdRp Flashplate scintillation proximity assay (Strep-Flash assay) used to evaluate analogues:

This assay consists on measuring the incorporation of [³H] radiolabelled UTP in a polyrA/ biotinylated-oligo dT template-primer, captured on the surface of streptavidin-coated microtiter flashplates (NEN SMP 103A). In brief, a 400 ng/ μ l polyrA solution (Amersham Pharmacia Biotech) was mixed volume-to-volume with 5' biotin-oligo dT₁₂ at 20 pmol/ μ l. The template and primers were denatured at 95 C for 5 minutes then incubated at 37 C for 10 minutes. Annealed template-primers were subsequently diluted in a Tris-HCl containing buffer and allowed to bind to streptavidin-coated flashplates overnight. Unbound material was discarded, compounds were added in a 10 μ l solution followed by a 10 μ l of a solution containing 100 mM MgCl₂, 200 mM Tris-HCl pH 7.5, 500 mM NaCl and 10 mM DTT. The enzymatic reaction was initiated upon addition of a 30 μ l solution containing the enzyme and substrate to obtain the following

concentrations: 25 μ M UTP, 1 μ Ci [3 H] γ -UTP and 100 nM recombinant HCV NS5B. RdRp reactions were allowed to proceed for 2 hrs at room temperature after which wells were washed three times with a 0.15 M NaCl solution, air dried at 37 C, and
5 counted in a Microbeta 1450 counter (Wallac). Results are shown in Table 1, in the column indicated as Assay 2.

Example 7 Evaluation of Biaryl Analogues for measurement of ATPase activity of HCV NS3 helicase

10

Measurement of ATPase activity for HCV NS3 helicase using the Malachite Green method:

The measurement of ATPase activity was performed by measuring
15 the amount of free inorganic phosphate released during the conversion of ATP to ADP by the HCV NS3 ATPase activity. The assay is as follows: In a 96-well microtiter-plate, compounds were dissolved at various concentrations in a final volume of 25 μ L of ATPase buffer containing 400 μ M ATP. The enzymatic
20 reaction was initiated by the addition of 25 μ l of ATPase buffer containing 6 nM of HCV NS3 enzyme without ATP to the wells followed by an incubation of 30 min. at 37 C. Essentially, the final concentration of the ATPase buffer components are as follows: 44 mM MOPS pH 7.0, 8.8 mM NaCl, 2.2 mM $MgCl_2$, 125 μ g/ml
25 poly A, 1% DMSO, 200 μ M ATP, and 3 nM HCV NS3 enzyme. The reaction was stopped by the addition of 100 μ l of Biomol GreenTM reagent (BIOMOL[®] Research Laboratories Inc., Plymouth Meeting, PA). In order to allow the development of the green color, the plate was incubated for 15 min. at room temperature. Then the
30 plate was read on a micro-plate reader at 620 nm. The 50% inhibitory concentration (IC_{50}) for anti-ATPase activity was defined as the concentration of compound that resulted in a 50 % reduction of the signal compared to the signal observed in control sample without compound. The signal recorded was also
35 corrected from the background signal obtained with control samples with compound only. The IC_{50} was determined from dose-response curves using six to eight concentrations per compound.

Curves were fitted to data points using a non-linear regression analysis, and IC_{50} s were interpolated from the resulting curves using GraphPad Prism software, version 2.0 (GraphPad Software Inc, San Diego, CA).

5





Measurement of ATPase activity of HCV NS3 helicase using the HPLC method:

10 The measurement of HCV NS3 ATPase activity was performed by measuring the amount of ADP produced during the conversion of ATP to ADP by the HCV NS3 enzyme using paired-ion HPLC on a reverse phase column. The assay is as follows: The same protocol as mentioned above was used except that the final
15 concentration of HCV NS3 enzyme was reduced to 1 nM in a 50 μ l reaction mixture and that the ATPase reaction was stopped by the addition of 12.5 μ l of 0.5 M EDTA. A modular liquid chromatography system (TSP Spectrasystem®, ThermoQuest Corporation, San Diego, USA) using a ChromQuest™ software
20 (ThermoQuest Corporation, San Diego, USA) controlled the autosampling of 25 μ l from each reaction. The mobile phase was an isocratic solution of 0.15 M triethylamine, 6% methanol, and phosphoric acid to pH 5.5. ADP and ATP peaks were resolved using the Aqua 5 μ , C18, 125 Å, (150 X 4.6 mm) reverse phase
25 column. The extent of ATP conversion to ADP was evaluated by measuring the area under the ADP peak produced which was detected at 259 nm. The amount of ADP was corrected for the presence of ADP contaminant in the original ATP solution. The 50% inhibitory concentration (IC_{50}) for anti-ATPase activity was
30 defined as the concentration of compound that resulted in a 50 % reduction of the ADP peak area compared to the ADP peak area observed in control sample without compound. The IC_{50} was determined from dose-response curves using six to eight concentrations per compound. Curves were fitted to data points
35 using a non-linear regression analysis, and IC_{50} s were interpolated from the resulting curves using GraphPad Prism software, version 2.0 (GraphPad Software Inc, San Diego, CA).




Results of the ATPase activity for HCV NS3 helicase are shown in Table 2.

$$\begin{array}{c}
 R_1 \\
 | \\
 R_3-M-N-C-R_2 \\
 | \quad | \quad | \\
 Y \quad A^1-A \\
 | \\
 Z \\
 | \\
 R_4
 \end{array}
 \quad (I)$$

wherein,


 (II) ;
 
 (III) ;
 
 (IV) ;
 
 (V) ;

,


 (VI) ;
 
 (VII) ;
 
 (VIII) ;
 a bond ;
 (IX)


A¹ is chosen from a bond, C₁₋₆ alkyl, C₂₋₆ alkenyl or C₂₋₆ alkynyl;

A is chosen from COOR_5 , CO-COOR_5 , $\text{PO}_3\text{R}_5\text{R}_5$, SO_3R_5 , tetrazole, $\text{CON(R}_5\text{)CH(R}_5\text{)-COOR}_5$, CONR_5R_5 , CONR_5OH , wherein each R_5 is independently chosen from H or C_{1-6} alkyl;

R₁, R₂ are independently chosen from H, C₁₋₆ alkyl, C₆₋₁₂ aryl, C₃₋₁₀ heterocycle, C₆₋₁₂ aralkyl or C₃₋₁₀ heteroaralkyl;

R₃ is chosen from C₆₋₁₂ aryl, C₃₋₁₀ heterocycle, C₆₋₁₂ aralkyl or C₃₋₁₀ heteroaralkyl;

Y is selected from the group consisting of:




Z is chosen from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₄ aryl, C₃₋₁₀ heterocycle;

R₄ is chosen from H, halogen, CN, NO₂, C₁₋₆ alkyl, C₆₋₁₂ aryl, C₃₋₁₀ heterocycle, C₆₋₁₂ aralkyl, C₃₋₁₀ heteroaralkyl, NR₅R₅, SO₂CH₃, O-C₁₋₆ alkyl, O-C₆₋₁₂ aryl, O-C₆₋₁₂ aralkyl, COR₇, wherein each R₅ is independently chosen from H or C₁₋₆ alkyl, and R₇ is chosen from C₆₋₁₂ aryl or C₃₋₁₀ heterocycle;

with the proviso that compound of formula (I) is other than 3-[3-(2,6-Dichloro-pyridin-4-yl)-1-(4-thiophen-2-yl-benzyl)-ureido]-3-thiophen-2-yl-propionic acid; compound #1 .

2. The compound as defined in claim 1, wherein R1 is chosen from benzyl, thiophene, CH2-thiophene, methyl, CH2-imidazole, CH2-cyclohexyl which can be unsubstituted or substituted by at least one substituent chosen from halogen, OH or benzyl.
3. The compound as defined in claim 1, wherein R1 is benzyl substituted with OH.
4. The compound as defined in claim 1, wherein R1 is benzyl substituted with Br.
5. The compound as defined in claim 1, wherein R1 is CH2-thiophene substituted with Br.

6. The compound as defined in claim 1, wherein R1 is CH2-cyclohexyl substituted with benzyl.
7. The compound as defined in claim 1, wherein M is chosen from:



(II)




(III)

a bond


(VIII)

8. The compound as defined in claim 1, wherein M is:



(II)

9. The compound as defined in claim 1, wherein M is:



(III)

10. The compound as defined in claim 1, wherein A is chosen from COOH or COOCH₂CH₃.
11. The compound as defined in claim 1, wherein A is COOH.
12. The compound as defined in claim 1, wherein A is COOCH₂CH₃.
13. The compound as defined in claim 1 wherein A1 is chosen from -CH₂, C=CH, CH-CH₂ or a bond.

14. The compound as defined in claim 1 wherein A1 is a bond.
15. The compound as defined in claim 1 wherein A1 is CH₂.
16. The compound as defined in claim 1 wherein R₃ is chosen from a C₆-12 aryl or C₃-10 heterocycle.
17. The compound as defined in claim 1 wherein R₃ is chosen from phenyl, pyridinyl, thiophenyl, benzofuran, thiazole, pyrazole, substituted with at least one substituent chosen from halogen, C₁-6 alkyl, C₂-6 alkenyl, OC₁-6 alkyl, CF₃, COOH, OH, COOC₁-6 alkyl, CN, NH₂, NO₂, NH(C₁-6 alkyl), N(C₁-6 alkyl)₂.
18. The compound of formula I, wherein said compound of formula I is chosen from:

(2s)-2-[(2,4-Dichloro-benzoyl)-(4-thiazol-2-yl-benzyl)-amino]-3-phenyl-propionic acid, compound #2

(2s)-2-[(4-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #3

(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #4

(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #5

(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #6

(2s)-2-[(3-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #7

3-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-thiophen-2-yl-propionic acid ethyl ester, compound #8

(2s)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #9

(2s)-2-[(3-Bromo-benzyl)-(2-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #10

(2s)-2-[(3-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #11

- (2s)-2-[(2,4-Dichloro-benzoyl)-(4-Iodo-benzyl)-amino]-3-phenyl-propionic acid, compound #12
- (2s)-2-[(3-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #13
- (2s)-2-[(4-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #14
- (2s)-2-[(3-Bromo-benzyl)-(4-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #15
- (2s)-2-[(4-Iodo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #16
- (2s)-2-[(3-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #17
- (2s)-5-(4-[(1s-1-Carboxy-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl)-phenyl-furan-2-carboxylic acid methyl ester, compound #18
- (2s)-2-[(3-Bromo-benzyl)-(3,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #19
- (2s)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #20
- (2s)-3-(1-Benzyl-1*h*-imidazol-4-yl)-2-[(3-bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-propionic acid, compound # 21
- (2s)-2-[(3-Bromo-benzyl)-[(2,4-dichloro-phenyl)-acetyl]-amino]-3-phenyl-propionic acid, compound #22
- (2s)-5-(4-[(1s-1-Carboxy-2-phenyl-ethyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-methyl)-phenyl-thiophene-2-carboxylic acid methyl ester, compound #23
- (2s)-2-[(2-Bromo-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #24
- (2s)-2-[(3-Bromo-benzyl)-(4-chloro-phenoxy-carbonyl)-amino]-3-phenyl-propionic acid, compound #25
- (2s)-2-[(4-Benzoyl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid
- (2s)-Triethyl-ammonium; 2-[(3-benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionate, compound #26
- 2-[Allyl-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid, compound #27
- (2s)-2-[(3-Bromo-benzyl)-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #28

3-(4-Benzofuran-2-yl-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #29
(2s)-2-[(3-Bromo-benzyl)-(2,4-dichloro-benzyl)-amino]-3-phenyl-propionic acid, compound #30
(2s)-2-[(3-Benzofuran-2-yl-benzyl)-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #31
(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid, compound #32
(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid, compound #33
(2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-methyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #34
(2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid, compound #35
(2s)-2-[(3-Bromo-benzyl)-(2-bromo-4-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #36
(2s)-2-[(3-Benzofuran-2-yl-benzyl)-[(2,4-dichloro-phenyl)-acetyl]-amino]-3-phenyl-propionic acid, compound #37
(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-phenyl)-amino]-3-phenyl-propionic acid, compound #38
(2s)-2-[(2,4-Dichloro-benzoyl)-naphthalen-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #39
(2s)-2-[(2,4-Dichloro-benzoyl)-(9,10-dioxo-9,10-dihydro-anthracen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #40
(2s)-2-[[3-(3-Chloro-benzoyl)-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #41
(2s)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-difluoro-benzoyl)-benzyl]-amino]-3-phenyl-propionic acid, compound # 42
(2s)-2-[[3-[3-(2-Chloro-phenyl)-5-methyl-isoxazole-4-carbonyl]-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound # 43
(2s)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-dichloro-benzoyl)-benzyl]-amino]-3-phenyl-propionic acid, compound #44
(2s)-2-[(3-Benzooxazol-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #45
(2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-ethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #46

(2s)-2-[(4-Benzofuran-2-yl-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-cyclohexyl-propionic acid, compound #47

(2s)-2-[(3-Benzofuran-2-yl-benzyl)-(4-chloro-2-methyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #48

(2s)-2-[(3-Benzofuran-2-yl-benzyl)-(2-bromo-4-chloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #49

(2s)-2-[(3-Bromo-benzyl)-(4-chloro-2-vinyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #50

(2s)-2-[(2,4-Dichloro-benzoyl)-(3-fluoro-benzyl)-amino]-3-phenyl-propionic acid, compound #51

(2s)-2-[(3-Chloro-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #52

(2S)-2-[(2,4-Dichloro-benzoyl)-(3-nitro-benzyl)-amino]-3-phenyl-propionic acid, Compound #53

(2S)-2-[(3-Cyano-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #54

(2s)-2-[(2-Chloro-benzoyl)-[5-(3-chloro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #55

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #56

(2s)-2-[(5-Bromo-furan-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #57

(2s)-2-[(5-Benzofuran-2-yl-furan-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #58

(2s)-2-[[5-(4-Bromo-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #59

(2s)-2-[[5-(2-Chloro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #60

(2s)-2-[[5-(2-Chloro-5-trifluoromethyl-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #61

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(2-nitro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #62

(3s)-3-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-4-phenyl-butyric acid, compound #63

2-[(2,4-Dichloro-benzoyl)-[2-(3-nitro-phenyl)-thiazol-5-ylmethyl]-amino]-3-phenyl-propionic acid, compound #64

- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3,4-dichloro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #65
- (2s)-2-[Benzofuran-2-ylmethyl-(2,4-dichloro-benzyl)-amino]-3-phenyl-propionic acid, compound #66
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(2,4-dichloro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #67
- (2s)-2-[(2-Bromo-4-chloro-benzoyl)-(5-bromo-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #68
- (2s)-2-[[5-(3-Chloro-4-fluoro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #69
- (2s)-2-[[5-(4-Chloro-3-fluoro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #70
- (2s)-2-[(5-Bromo-furan-2-ylmethyl)-(4-chloro-2-iodo-benzoyl)-amino]-3-phenyl-propionic acid, compound #71
- (2s)-2-(5-{[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-furan-2-yl)-benzoic acid ethyl ester, compound #72
- (2s)-2-(5-{[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-furan-2-yl)-benzoic acid, compound #73
- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-thiazol-2-yl-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #74
- (2s)-2-[(2,4-Dichloro-benzoyl)-furan-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #75
- (2s)-3-(5-{[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-furan-2-yl)-benzoic acid, compound #76
- (2s)-4-(5-{[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-furan-2-yl)-benzoic acid, compound #77
- (2s)-2-[(2-Bromo-4-chloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #78
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3,5-difluoro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #79
- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-m-tolyl-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #80
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-fluoro-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #81
- (2s)-2-[(5-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #82

(2s)-4-(5-{[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-thiophen-2-yl)-benzoic acid, compound #83

(2s)-4-(5-{[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl}-thiophen-2-yl)-benzoic acid methyl ester, compound #84

(2s)-2-[(5-Benzofuran-2-yl-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #85

2-[(2-Benzofuran-2-yl-thiazol-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #86

(2s)-2-[(2,4-Dichloro-benzoyl)-[4-(3,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #87

(2s)-2-[[4-(4-Chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #88

(2s)-2-[[4-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #89

(2s)-2-[(2,4-Dichloro-benzoyl)-[4-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #90

(2s)-2-[[5-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #91

(2s)-2-[[5-(4-chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #92

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #93

(2s)-2-[(2,4-Dichloro-benzoyl)-(5-thiazol-2-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #94

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #95

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #96

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #97

(2s)-2-[(2,4-Dichloro-benzoyl)-thiophen-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #98

(2s)-2-[(4-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #99

(2s)-2-[(2,4-Dichloro-benzoyl)-[2-(4-phenyl-piperazin-1-yl)-thiazol-5-ylmethyl]-amino]-3-phenyl-propionic acid, compound #100

(2s)-1-(5-[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiazol-2-yl)-piperidine-4-carboxylic acid, compound #101

(2s)-2-[[2-(4-Benzyl-piperazin-1-yl)-thiazol-5-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #102

(2s)-2-[(2,4-Dichloro-benzoyl)-(2-piperidin-1-yl-thiazol-5-ylmethyl)-amino]-3-phenyl-propionic acid, compound #103

(2s)-2-[(2,4-Dichloro-benzoyl)-(2-diethylamino-thiazol-5-ylmethyl)-amino]-3-phenyl-propionic acid, compound #104

(2s)-2-[[2-(4-Chloro-benzoyl)-benzofuran-3-ylmethyl]-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #105

(2s)-2-[[5-(2,4-Dichloro-phenoxy)-1-methyl-3-trifluoromethyl-1h-pyrazol-4-ylmethyl]-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-3-phenyl-propionic acid, compound #106

(2s)-2-[(2,4-Dichloro-benzoyl)-{2-[5-(2,4-dichloro-phenyl)-furan-2-yl]-2-oxo-ethyl}-amino]-3-phenyl-propionic acid, compound #107

(2s)-2-Benzyl-4-(2,4-dichloro-phenyl)-3-[3-(2,6-dichloro-phenyl)-5-methyl-isoxazol-4-ylmethyl]-4-oxo-butyric acid, compound #108

(2s)-2-[Allyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #109

(2s)-2-[(2,4-Dichloro-benzoyl)-methyl-amino]-3-phenyl-propionic acid, compound #110

(2s)-2-[(2,4-Dichloro-benzoyl)-prop-2-ynyl-amino]-3-phenyl-propionic acid, compound #111

(2s)-2-[(2,4-Dichloro-benzoyl)-propyl-amino]-3-phenyl-propionic acid, compound #112

(2s)-2-[(3-Benzofuran-2-yl-prop-2-ynyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #113

(2s)-2-[(4-Benzofuran-2-yl-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #114

(2s)-2-[(2,4-Dichloro-benzoyl)-(3-methyl-but-2-enyl)-amino]-3-phenyl-propionic acid, compound #115

2-[(2-Bromo-allyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #116

3-[[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid methyl ester, compound #117

3-[[5-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-5-phenyl-thiophene-2-carboxylic acid, compound #118

2-[[5-(3-Cyano-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #119

(2s)-2-[(2,4-Dichloro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #120

(2s)-2-(5-[[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-thiophen-2-yl)-benzoic acid ethyl ester, compound #121

3-(5-[[(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-thiophen-2-yl)-benzoic acid ethyl ester, compound #122

(2s)-2-[[5-(3-Chloro-phenyl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #123

(2s)-2-[(4-Chloro-2-iodo-benzoyl)-(3,5-dibromo-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #124

(2s)-3-(5-[[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-thiophen-2-yl)-benzoic acid, compound #125

(2s)-2-[[5-(5-Chloro-thiophen-2-yl)-furan-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #126

(2s)-2-[[2,2']Bithiophenyl-5-ylmethyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #127

(2s)-2-[(5'-Chloro-[2,2']bithiophenyl-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #128

(2s)-2-[(2,4-Dichloro-benzoyl)-[4-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #129

(2s)-2-[(2,4-Dichloro-benzoyl)-[4-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #130

(2s)-2-[(4-Chloro-2-iodo-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #131

- (2s)-2-[(4-Chloro-2-methyl-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #132
- (2s)-2-[(5-Chloro-[2,3']bithiophenyl-5'-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #133
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(4-methoxy-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #134
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(4-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #135
- (2s)-2-[(2,4-Dichloro-benzoyl)-[4-(4-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #136
- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-pyridin-4-yl-furan-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #137
- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #138
- (2s)-2-[(2,4-Dichloro-benzoyl)-(4-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #139
- (2s)-2-[(2-Chloro-thiazol-5-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #140
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #141
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3,5-dichloro-benzyl)-amino]-3-phenyl-propionic acid, compound #142
- (2s)-2-[(2,4-Dichloro-benzoyl)-thiophen-3-ylmethyl-amino]-3-phenyl-propionic acid, compound #143
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid, compound #144
- (2s)-2-[[3-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #145
- (2s)-2-[(3-Bromo-thiophen-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #146
- (2s)-2-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-2-methyl-propionic acid, compound #147
- (2s)-2-[(2,4-Dichloro-benzoyl)-[2-(3-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-amino]-3-phenyl-propionic acid, compound #148
- (2s)-2-[(2,4-Dichloro-benzoyl)-(5-nitro-thiophen-3-ylmethyl)-amino]-3-phenyl-propionic acid, compound #149

- (2s)-2-[(2,4-Dichloro-benzoyl)-(4-methanesulfonyl-benzyl)-amino]-3-phenyl-propionic acid, compound #150
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3-methoxy-benzyl)-amino]-3-phenyl-propionic acid, compound #151
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3-methyl-benzyl)-amino]-3-phenyl-propionic acid, compound #152
- (2s)-2-[[5-(3-Chloro-phenoxy)-1-methyl-3-trifluoromethyl-1H-pyrazol-4-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #153
- (2s)-2-[(2,4-Dichloro-benzoyl)-[3-(3,5-difluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #154
- (2s)-2-[(2,4-Dichloro-benzoyl)-[3-(3,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #155
- (2s)-2-[[3-(4-Chloro-3-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #156
- (2s)-2-[(2,4-Dichloro-benzoyl)-[3-(2,4-dichloro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #157
- (2s)-2-[(2,4-Dichloro-benzoyl)-(3-*m*-tolyl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #158
- (2s)-2-(2-([(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-3-yl)-benzoic acid ethyl ester, compound #159
- (2s)-4-(2-([(1s-1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-thiophen-3-yl)-benzoic acid ethyl ester, compound #160
- (2s)-2-[(2,4-Dichloro-benzoyl)-[3-(3-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #161
- (2s)-2-[[3-(3-Cyano-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #162
- {(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino}-thiophen-2-yl-acetic acid, compound #163
- L-2-([(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl)-pyrrolidine-1-carboxylic acid *tert*-butyl ester, compound #164

d-2-[[(1-carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-pyrrolidine-1-carboxylic acid #tert!-butyl ester, compound #165

4-[(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-piperidine-1-carboxylic acid benzyl ester, compound #166

1-2-[(2,4-Dichloro-benzoyl)-pyrrolidin-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #167

d-2-[(2,4-Dichloro-benzoyl)-pyrrolidin-2-ylmethyl-amino]-3-phenyl-propionic acid, compound #168

3-(5-Bromo-thiophen-2-yl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #169

2-[(2,4-Dichloro-benzoyl)-pyridin-3-ylmethyl-amino]-3-phenyl-propionic acid, compound #170

2-[(2,4-Dichloro-benzoyl)-(4-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid, compound #171

2-[(2,4-Dichloro-benzoyl)-[4-(4-fluoro-benzyloxy)-benzyl]-amino]-3-phenyl-propionic acid, compound #172

2-[(2,4-Dichloro-benzoyl)-(4-fluoro-3-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid, compound #173

2-[(1-Benzenesulfonyl-1h-pyrrol-2-ylmethyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #174

2-[[3-(4-Chloro-phenoxy)-benzyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #175

2-[(5-Chloro-2-chloromethyl-hepta-2,4,6-trienoyl)-quinolin-3-ylmethyl-amino]-3-phenyl-propionic acid, compound #176

2-[(2-Benzyloxy-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #177

2-[(2,4-Dichloro-benzoyl)-[3-(5-isopropyl-2-methoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #178

2-[(2,4-Dichloro-benzoyl)-[3-(4-trifluoromethoxy-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #179

2-[(2,4-Dichloro-benzoyl)-[3-(3-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #180

2-[[3-(3,5-Bis-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #181

- 2-[(2,4-Dichloro-benzoyl)-(3-pyridin-4-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #182
- 2-[(2,4-Dichloro-benzoyl)-[3-(4-methylsulfanyl-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #183
- 2-[(2,4-Dichloro-benzoyl)-[3-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #184
- 2-[(2,4-Dichloro-benzoyl)-(3-pyridin-3-yl-thiophen-2-ylmethyl)-amino]-3-phenyl-propionic acid, compound #185
- 2-[(2,4-Dichloro-benzoyl)-[1-(toluene-2-sulfonyl)-pyrrolidin-2-ylmethyl]-amino]-3-phenyl-propionic acid, compound #186
- 2-[(2-Bromo-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #187
- 3-(2-Bromo-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #188
- 3-(4-Bromo-phenyl)-2-[(2,4-dichloro-benzoyl)-methyl-amino]-propionic acid, compound #189
- 2-[(3-Bromo-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #190
- 2-[(4-Bromo-phenyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #191
- 2-[[[4-(3-Chloro-4-fluoro-phenyl)-thiophen-2-ylmethyl]-(2,4-dimethyl-benzoyl)-amino]-3-phenyl-propionic acid, compound #192
- 3-[[[1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid, compound #193
- 2-[(3-Amino-benzyl)-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid, compound #194
- 3-Phenyl-2-[(2-trifluoromethyl-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-propionic acid, Compound #195
- 2-[(3-Cyano-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, Compound #196
- 2-[(4-Nitro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, Compound #197
- 2-[(2-Fluoro-benzoyl)-[5-(2-trifluoromethyl-phenyl)-furan-2-ylmethyl]-amino]-3-phenyl-propionic acid, Compound #198
- 2-[Benzyl-(2,4-dichloro-benzoyl)-amino]-3-phenyl-propionic acid
Compound #199

2-[(2,4-DICHLORO-BENZOYL)-(3-(2H-TETRAZOL-5-YL)-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #200

2-[(2,4-DICHLORO-BENZOYL)-(2-NITRO-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #201

2-[(2,4-DICHLORO-BENZOYL)-(4-NITRO-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #202

2-[(2-CYANO-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #203

2-[(4-CYANO-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #204

2-[[1-(3-CYANO-PHENYL)-ETHYL]-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #205

3-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid methyl ester Compound #206

3-[[1-(1-Carboxy-2-phenyl-ethyl)-(2,4-dichloro-benzoyl)-amino]-methyl]-benzoic acid Compound #207

2-[(2,4-DICHLORO-BENZOYL)-(3-METHANESULFONYL-BENZYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #208

2-[(3-ACETYL-BENZYL)-(2,4-DICHLORO-BENZOYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #209

2-[(2,4-DICHLORO-BENZOYL)-(1-OXY-PYRIDIN-3-YLMETHYL)-AMINO]-3-PHENYL-PROPIONIC ACID Compound #210

2-[(2,4-Dichloro-benzoyl)-[5-(3-trifluoromethyl-phenyl)-thiophen-2-ylmethyl]-amino]-3-phenyl-propionic acid Compound #211.

19. A pharmaceutical composition for treating or preventing a *Flaviviridae* viral infection comprising administering at least one compound according to formula (I) as defined in

anyone of claims 1 to 18, together with at least one pharmaceutically acceptable carrier or excipient.

20. A pharmaceutical composition as defined in claim 19, further comprising one or more additional agent chosen from antiviral agent, immunomodulating agent, antioxidant agent, antibacterial agent or antisense agent.
21. The pharmaceutical composition as defined in claim 20, wherein the antiviral agent is chosen from a viral serine protease inhibitor, viral polymerase inhibitor and viral helicase inhibitor.
22. The pharmaceutical composition as defined in claim 20, wherein the antiviral agent is chosen from interferon α and ribavirin.
23. The pharmaceutical composition as defined in claim 20, wherein said additional agent is chosen from silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
24. The composition as defined in anyone of claims 19 to 23 wherein said *Flaviviridae* viral infection is hepatitis C viral infection (HCV).
25. The use of a compound according to formula (I) as defined in anyone of claims 1 to 18, for the manufacture of a medicament for treating or preventing a viral *Flaviviridae* infection in a host.
26. The use as defined in claim 25, wherein said *Flaviviridae* infection is hepatitis C viral infection (HCV).
27. The use of a compound according to formula (I) as defined in anyone of claims 1 to 18, for use in therapy.

28. The use of a compound according to formula (I) as defined in anyone of claims 1 to 18, for treating or preventing *Flaviviridae* viral infection in a host.
29. The use of a compound as defined in claim 28, further comprising one or more additional agent chosen from antiviral agent, immunomodulating agent, antioxydant agent, antibacterial agent or antisense agent.
30. The use as defined in claim 29, wherein said antiviral agent is chosen from a viral serine protease inhibitor, viral polymerase inhibitor and viral helicase inhibitor.
31. The use as defined in claim 29, wherein said antiviral agent is chosen from interferon α and ribavirin.
32. The use as defined in claim 29, wherein said additional agent is chosen from silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
33. The use as defined in anyone of claims 29 to 32, wherein said compound and said additional agent are administered sequentially.
34. The use as defined in anyone of claims 29 to 32, wherein said compound and said additional agent are administered simultaneously.
35. The use as defined in anyone of claims 28 to 34, wherein said *Flaviviridae* viral infection is hepatitis C viral infection (HCV).
36. The use of a compound according to formula (I) as defined in anyone of claims 1 to 18 for inhibiting or reducing the activity of viral polymerase in a host.
37. The use as defined in claim 36 further comprising one or more viral polymerase inhibitor.

38. The use as defined in anyone of claims 36 or 37, wherein said viral polymerase is *Flaviviridae* viral polymerase.
39. The use as defined in anyone of claims 36 or 37, wherein said viral polymerase is RNA-dependant RNA-polymerase.
40. The use as defined in anyone of claims 36 or 37, wherein said viral polymerase is HCV polymerase.
41. The use of a compound according to formula (I) as defined in anyone of claims 1 to 18 for inhibiting or reducing the activity of viral helicase in a host.
42. The use as defined in claim 41 further comprising one or more viral helicase inhibitor.
43. The use as defined in anyone of claims 41 or 42, wherein said viral helicase is *Flaviviridae* viral helicase.
44. The use as defined in anyone of claims 41 or 42, wherein said viral helicase is HCV helicase.
45. A combination comprising a compound according to formula (I) as defined in anyone of claims 1 to 18 and one or more additionnal agent chosen from viral serine protease inhibitor, viral polymerase inhibitor and viral helicase inhibitor, immunomodulating agent, antioxydant agent, antibacterial agent or antisense agent.
46. The combination as defined in claim 45, wherein said additional agent is chosen from silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine, cyclosporin, interferon α and ribavirin.
47. The combination as defined in anyone of claims 45 or 46, wherein said compound and said additionnal agent are administered sequentially.

48. The combination as defined in anyone of claims 45 or 46, wherein said compound and said additionnal agent are administered simultaneously.

INTERNATIONAL SEARCH REPORT

Intern: Application No
PCT/CA 02/00877

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D277/28 C07C233/87 C07D307/81 C07D333/24 C07C311/29
 C07C311/19 C07D233/54 C07D261/08 C07D263/56 C07D307/52
 C07D407/04 C07D417/04 C07D333/20 C07D409/04 C07D231/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 606 046 A (CIBA GEIGY AG) 13 July 1994 (1994-07-13) Intermed. of Ex. 1-4,7,8,9,11,17-22,27-29	1,2,7,8, 10,11, 13,14, 16,17,27
X,P	WO 02 00606 A (WATANABE HIROYUKI ;ASO KAZUYOSHI (JP); MIWA TETSUO (JP); SANTO TAK) 3 January 2002 (2002-01-03) page 221	1-3,7,9, 10, 12-14, 16,17,27
X	WO 00 43369 A (SEMKO CHRISTOPHER ;SOARES CHRISTOPHER JOSEPH (US); TARBAY CHRISTINE) 27 July 2000 (2000-07-27) page 100 --- -/--	1,2,7, 10,11, 13,14, 16,27

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
 E earlier document but published on or after the international filing date
 I document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 O document referring to an oral disclosure, use, exhibition or other means
 P document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 & document member of the same patent family

Date of the actual completion of the international search

19 September 2002

Date of mailing of the international search report

09/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/CA 02/00877

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D207/09 C07D211/58 A61K31/44 A61K31/425 A61K31/40
A61K31/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 37436 A (HOFFMANN LA ROCHE) 29 June 2000 (2000-06-29) examples 47,137 ----	1,7,8, 13,14, 16,27
X	WO 00 15213 A (SHIMAMURA TOSHITAKE ;TSUZUKI HIROSHIGE (JP); WATANABE FUMIHIKO (JP) 23 March 2000 (2000-03-23) examples 403,408,410,412,415,419 ----	1,2,7,8, 13,14, 16,27
X	WO 00 03743 A (BERLIN VIVIAN ;MITOTIX INC (US); BERGNES GUSTAVE (US); COME JON (U) 27 January 2000 (2000-01-27) figure 67; examples 121,122 ----- -/-	1,7,9, 13,14,16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

19 September 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

 Intern application No
 PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 03166 A (MCDONALD JOSEPH J ;MONSANTO CO (US); ABBAS ZAHEER S (US); FRESKOS) 29 January 1998 (1998-01-29) examples 56B, 57B ---	1, 2, 7, 8, 13, 14, 16, 27
X	WO 96 38419 A (NISSAN CHEMICAL IND LTD ;AKIYAMA SHIGEAKI (JP); SUZUKI HIROYUKI (J) 5 December 1996 (1996-12-05) compound 2-498 ---	1, 7, 8, 13, 14, 16, 17
X	WO 95 12611 A (JAPAT LTD ;FRUEH THOMAS (CH); PITTERNA THOMAS (CH); SVENSSON LENE) 11 May 1995 (1995-05-11) Interm. of Ex. 16, 17 ---	1, 2, 6, 7, 9-11, 13, 14, 16, 27
X	WO 91 12002 A (MERCK & CO INC) 22 August 1991 (1991-08-22) examples 7, 8 ---	1, 2, 10, 11, 13, 14, 16, 27
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 09, 13 October 2000 (2000-10-13) -& JP 2000 159610 A (HOKKO CHEM IND CO LTD), 13 June 2000 (2000-06-13) abstract; examples 736-740 ---	1, 2, 7, 9, 13, 14, 16
X	PATENT ABSTRACTS OF JAPAN vol. 1995, no. 05, 30 June 1995 (1995-06-30) -& JP 07 048360 A (YOSHITOMI PHARMACEUT IND LTD), 21 February 1995 (1995-02-21) abstract; examples 14, 15 ---	1, 2, 7, 9-11, 13, 14, 16, 27
X, P	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CARCELLER, ELENA ET AL: "Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity" retrieved from STN Database accession no. 135:288736 XP002214049 RNs 188913-69-1, 365425-88-3, 188913-68-0 & JOURNAL OF MEDICINAL CHEMISTRY (2001), 44(18), 3001-3013 , --- -/--	1, 7, 8, 13, 14, 16, 27

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DASGUPTA, FALGUNI ET AL: "Peptoids as endothelin receptor antagonists" retrieved from STN Database accession no. 134:340674 XP002214050 RNs 338403-19-3; 338403-23-9, 338403-17-1, 338403-21-7 & BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001), 11(4), 555-557 ,</p>	1,7, 9-14,16, 17,27
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PIRO, J. ET AL: "Solid phase synthesis of enantiomerically pure polyhydroxyvalerolactams" retrieved from STN Database accession no. 134:326374 XP002214051 RN 336110-47-5 & TETRAHEDRON LETTERS (2001), 42(5), 871-873 ,</p>	1,7,8, 13,14,16
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SVENSSON, ANETTE ET AL: "Preparation of Fluorinated Linkers: Use of 19F NMR Spectroscopy to Establish Conditions for Solid-Phase Synthesis of Peptide Libraries" retrieved from STN Database accession no. 134:71849 XP002214052 RN 314241-13-9 & JOURNAL OF COMBINATORIAL CHEMISTRY (2000), 2(6), 736-748 ,</p> <p style="text-align: center;">--- -/--</p>	1,2,7, 9-11,13, 14,16

INTERNATIONAL SEARCH REPORT

 Interr I Application No
 PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIN, XIAODONG ET AL: "Utilization of Fukuyama's sulfonamide protecting group for the synthesis of N-substituted.alpha.-amino acids and derivatives" retrieved from STN Database accession no. 133:164289 XP002214053 RN 287918-72-3 & TETRAHEDRON LETTERS (2000), 41(18), 3309-3313 ,	1,7,8, 10,11, 13,14, 16,17
X	--- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TURNER, JOHN J. ET AL: "Mitsunobu glycosylation of nitrobenzenesulfonamides: novel route to Amadori rearrangement products" retrieved from STN Database accession no. 131:299628 XP002214054 RNs 247167-15-3, 247167-20-0 & TETRAHEDRON LETTERS (1999), 40(38), 7039-7042 ,	1,2,7,8, 10,11, 13,14, 16,17
X	--- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CALDARELLI, MARINA ET AL: "Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents" retrieved from STN Database accession no. 131:272149 XP002214055 RNs 245364-86-7, 245364-88-9, 245364-90-3, 245364-91-4, 245364-92-5, 245364-93-6, 245364-94-7, 245364-95-8, 245364-96-9 & BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (1999), 9(14), 2049-2052 ,	1,2,7,8, 13,14, 16,17,27
	--- -/--	

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BOURNE, GREGORY T. ET AL: "A Backbone Linker for BOC-Based Peptide Synthesis and On-Resin Cyclization: Synthesis of Stylostatin 1" retrieved from STN Database accession no. 130:352526 XP002214056 RN 224824-95-7 & JOURNAL OF ORGANIC CHEMISTRY (1999), 64(9), 3095-3101 ,</p> <p>---</p>	1,2,7, 9-11,13, 14,16
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DONDE, YARIV ET AL: "High Enantioselection in the Rearrangement of Allylic Imidates with Ferrocenyl Oxazoline Catalysts" retrieved from STN Database accession no. 130:324989 XP002214057 RN 223791-90-0 & JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (1999), 121(12), 2933-2934 ,</p> <p>---</p>	1,2,7,9, 13,14,16
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WILSON, MICHAEL W. ET AL: "A facile rearrangement of N-alkyl, N-(o or p-nitrophenylsulfonamide)-.alpha.-amino esters" retrieved from STN Database accession no. 130:237845 XP002214058 RN 221285-55-8 & TETRAHEDRON (1999), 55(6), 1647-1656 ,</p> <p>---</p> <p style="text-align: center;">-/--</p>	1,2,7,8, 13,14, 16,17

INTERNATIONAL SEARCH REPORT

 Internat Application No
 PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAWASE, MASAMI ET AL: "A general method for the preparation of 5-trifluoromethylated oxazoles from.alpha.-amino acids" retrieved from STN Database accession no. 129:81683 XP002214059 RN 154177-56-7 & CHEMICAL & PHARMACEUTICAL BULLETIN (1998), 46(5), 749-756 ,	1,2,7,9, 13,14,16
X	----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; REICHWEIN, JOHN F. ET AL: "Site-specific N-alkylation of peptides on the solid phase" retrieved from STN Database accession no. 128:205125 XP002214060 RN 203873-76-1 & TETRAHEDRON LETTERS (1998), 39(10), 1243-1246 ,	1,7,8, 10,11, 13,14,16
X	----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FUKUYAMA, TOHRU ET AL: "2,4-Dinitrobenzenesulfonamides: a simple and practical method for the preparation - of a variety of secondary amines and diamines" retrieved from STN Database accession no. 127:262477 XP002214061 RN 196214-54-7 & TETRAHEDRON LETTERS (1997), 38(33), 5831-5834 ,	1-14,16, 17
	----- -/--	

INTERNATIONAL SEARCH REPORT

Intern: pplication No

PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DANKWARDT, SHARON M. ET AL: "Solid-phase synthesis of N-alkyl sulfonamides" retrieved from STN Database accession no. 127:220959 XP002214062 RNs 195052-44-9, 195052-48-3 & SYNLETT (1997), (7), 854-856 ,</p>	1,2,7,8, 10,11, 13,14, 16,17
X	<p>----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XIAO, MIN ET AL: "Diastereoselective synthesis of drugs: preparation of (S,S)-2-hydroxyl-3-amino-4-phenylbutyric acid" retrieved from STN Database accession no. 126:186342 XP002214063 RN 187528-37-6 & HUAXUE SHIJI (1996), 18(6), 324-326,336 ,</p>	1,2,7, 9-11,13, 14,16
X	<p>----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; RU, QI ET AL: "Diastereoselective synthesis of (2S,3S)-3-amino-2-hydroxy-4- phenylbutyric acid: core unit of HIV protease inhibitors" retrieved from STN Database accession no. 123:33607 XP002214064 RN 164122-43-4 & ZHONGGUO YIYAO GONGYE ZAZHI (1994), 25(12), 557-9 ,</p>	1,2,7, 9-11,13, 14,16
X	<p>----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAWASE, MASAMI: "A facile one-pot synthesis of 5-trifluoromethyl- and 5-perfluoroalkyloxazoles from N-alkyl-N-acylamino acids" retrieved from STN Database accession no. 120:270195 XP002214065 RN 154177-56-7 & HETEROCYCLES (1993), 36(11), 2441-4 ,</p> <p>----- -/-</p>	1,2,7,9, 13,14,16

INTERNATIONAL SEARCH REPORT

 Internl Application No
 PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FURUTA, TAKUYA ET AL: "Preparation of indole derivatives as vasopressin antagonists" retrieved from STN Database accession no. 116:128656 XP002214066 RN 138121-08-1 & JP 03 127732 A (OTSUKA PHARMACEUTICAL CO., LTD., JAPAN) 30 May 1991 (1991-05-30) ---	1,7,9, 13,14, 16,17,27
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAITO, TAKEAKI ET AL: "A new synthesis of 2-amino-.gamma.-lactones involving photochemical addition reaction of alcohols to enamide" retrieved from STN Database accession no. 110:23649 XP002214067 RNs 118119-88-3, 118119-89-4, 118119-90-7 & HETEROCYCLES (1988), 27(6), 1325-7 , ---	1,7,9, 13,14,16
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GELLERT, EMERY ET AL: "Stereospecific synthesis of hexahydrobenzopyrroloisoquinoline and tetrahydrobenzisoquinoline derivatives" retrieved from STN Database accession no. 101:110700 XP002214068 RNs 91462-69-0, 91462-70-3 & AUST. J. CHEM. (1984), 37(4), 819-29 , ---	1,7,8, 10,11, 13,14, 16,17
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOSHIOKA, TADAO ET AL: "Synthesis of oxazolyindole alkaloids from tryptamine and tryptophan by oxidation with 2,3-dichloro-5,6-dicyanobenzoquinone" retrieved from STN Database accession no. 95:187495 XP002214069 RN 79659-75-9 & J. CHEM. RES., SYNOP. (1981), (7), 194-5 , --- -/--	1,2,7,9, 13,14,16

INTERNATIONAL SEARCH REPORT

Intern: .pplication No

PCT/CA 02/00877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HITCHINGS, ERIC J. ET AL: "Degradation of the herbicide flamprop-isopropyl in soil under laboratory conditions" retrieved from STN Database accession no. 92:35802 XP002214070 RN 72274-16-9 & PESTIC. SCI. (1979), 10(1), 1-13 ,</p>	1,2,7, 9-11,13, 14,16
X	<p>----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; EL AZZOUNY, AIDA ET AL: "Synthesis of acyclic and cyclic anthranilic acid-phenylalanine peptides". retrieved from STN Database accession no. 88:23352 XP002214071 RNs 65002-31-5, 65002-24-6 & PHARMAZIE (1977), 32(6), 318-23 ,</p>	1,2,7, 9-11,13, 14,16,17
A	<p>----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MIKHALEV, A. I. ET AL: "Quinolino'2,1-b!quinazolin-12-one-5-carbo xylic cyclohexylamide having antiflaviviral activity" retrieved from STN Database accession no. 133:217678 XP002214072 abstract & RU 2 130 023 C (PERMSKAYA GOSUDARSTVENNAYA FARMATSEVTICHESKAYA AKADEMIYA, RUSSIA) 10 May 1999 (1999-05-10) -----</p>	1-48

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-17,19-48 relate to an extremely large number of possible compounds. In fact, the "basic" structure as figured in formula (I) is made only of variables, except a nitrogen atom. Many options, variables, possible permutations are contained in such a definition that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, based on those compounds recited in the examples and closely related homologous compounds, especially wherein A = -COOR₅; M = CO, SO₂, CH₂-CO, O-CH₂-CO, bond; R₁ = Ring-CH₂-; R₂ = H, alkyl; R₃ = Ring; A₁ = bond or CH₂; Y = CH₂ or CH₂CO; Z = Ring (Ring = aryl or heterocycle).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

In International application No.
PCT/CA 02/00877

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: Application No
PCT/CA 02/00877

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0606046	A	13-07-1994	US 5455258 A	03-10-1995
			AT 159012 T	15-10-1997
			AU 684255 B2	11-12-1997
			AU 5265593 A	04-05-1995
			BR 1100131 A3	14-03-2000
			CA 2112779 A1	07-07-1994
			DE 69314456 D1	13-11-1997
			DE 69314456 T2	26-02-1998
			DK 606046 T3	04-05-1998
			EP 0606046 A1	13-07-1994
			ES 2107648 T3	01-12-1997
			FI 940012 A	07-07-1994
			GR 3025611 T3	31-03-1998
			HK 1002633 A1	04-09-1998
			HU 70536 A2	30-10-1995
			IL 108229 A	30-10-1998
			JP 2951527 B2	20-09-1999
			JP 6256293 A	13-09-1994
			MX 9400276 A1	29-07-1994
			NO 940038 A ,B,	07-07-1994
			NZ 250517 A	26-10-1995
			SG 42933 A1	17-10-1997
			US 5506242 A	09-04-1996
			US 5552419 A	03-09-1996
			US 5646167 A	08-07-1997
			US 5672615 A	30-09-1997
			ZA 9400048 A	11-08-1994
WO 0200606	A	03-01-2002	AU 6634601 A	08-01-2002
			WO 0200606 A1	03-01-2002
			JP 2002080439 A	19-03-2002
WO 0043369	A	27-07-2000	AU 2623900 A	07-08-2000
			AU 3472400 A	07-08-2000
			BR 0007663 A	07-05-2002
			CN 1351592 T	29-05-2002
			CN 1346350 T	24-04-2002
			CZ 20012361 A3	12-12-2001
			EP 1144384 A1	17-10-2001
			EP 1144388 A1	17-10-2001
			NO 20013600 A	20-09-2001
			WO 0043369 A1	27-07-2000
WO 0037436	A	29-06-2000	WO 0043372 A1	27-07-2000
			AU 1979200 A	12-07-2000
			BR 9916504 A	11-09-2001
			CN 1331674 T	16-01-2002
			CZ 20012294 A3	12-12-2001
			WO 0037436 A1	29-06-2000
			EP 1149072 A1	31-10-2001
			HR 20010443 A1	30-06-2002
			NO 20013100 A	21-08-2001
			PL 349449 A1	29-07-2002
WO 0015213	A	23-03-2000	TR 200101868 T2	21-11-2001
			AU 5647099 A	03-04-2000
			WO 0015213 A1	23-03-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern

Application No

PCT/CA 02/00877

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0003743	A	27-01-2000	US 6423519 B1 AU 5107599 A EP 1096925 A2 JP 2002520372 T WO 0003743 A2	23-07-2002 07-02-2000 09-05-2001 09-07-2002 27-01-2000
WO 9803166	A	29-01-1998	AU 740263 B2 AU 3890397 A BR 9710752 A CN 1238688 A CZ 9900168 A3 EP 0939629 A1 JP 2000515153 T NO 990247 A NZ 333825 A NZ 506464 A PL 331338 A1 WO 9803166 A1	01-11-2001 10-02-1998 17-08-1999 15-12-1999 11-08-1999 08-09-1999 14-11-2000 19-03-1999 27-10-2000 28-06-2002 05-07-1999 29-01-1998
WO 9638419	A	05-12-1996	AU 5845096 A WO 9638419 A1 JP 9176125 A	18-12-1996 05-12-1996 08-07-1997
WO 9512611	A	11-05-1995	AU 691201 B2 AU 7856594 A BR 9407933 A CA 2173875 A1 WO 9512611 A1 EP 0728145 A1 FI 961804 A NO 961725 A RU 2126418 C1 US 5780498 A ZA 9408541 A	14-05-1998 23-05-1995 26-11-1996 11-05-1995 11-05-1995 28-08-1996 30-04-1996 29-04-1996 20-02-1999 14-07-1998 02-05-1995
WO 9112002	A	22-08-1991	CA 2075621 A1 EP 0515548 A1 JP 5504359 T WO 9112002 A1 US 5183810 A	14-08-1991 02-12-1992 08-07-1993 22-08-1991 02-02-1993
JP 2000159610	A	13-06-2000	NONE	
JP 07048360 0	A		NONE	
JP 3127732	A	30-05-1991	JP 2769578 B2	25-06-1998
RU 2130023	C	10-05-1999	RU 2130023 C1	10-05-1999